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ABSTRACT

Lung metastasis remains a leading cause of death in breast cancer patients. This
study established an innovative 3D ex vivo pulmonary metastasis assay (PuMA) to test
the hypothesis that the lung microenvironment promotes metastatic behaviour of whole
population and stem-like ALDHhiCD44+ breast cancer cells. Following in vivo delivery of
breast cancer cells to mice, lungs were excised, maintained in culture and imaged to
observe breast cancer growth over time. We observed metastatic progression of breast
cancer cells in the PuMA, most notably of ALDHhiCD44+ cells which progressed rapidly
from single cells to multicellular colonies over 21 days relative to their ALDHloCD44counterparts (p≤0.05). Although soluble lung-derived bFGF induced breast cancer cell
proliferation in vitro, blocking bFGF in the PuMA showed only a trend towards inhibition
of breast cancer cell growth. This model system will be valuable for elucidating the
interaction between breast cancer cells and the lung during metastatic progression.

Keywords: Breast cancer, metastasis, organ-specific tropism, pulmonary metastasis
assay (PuMA), cancer stem cell, aldehyde dehydrogenase (ALDH), CD44, basic
fibroblast growth factor (bFGF).
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1.

INTRODUCTION
Despite earlier screening and ongoing research in the areas of cancer treatment

and prevention, cancer remains the leading cause of death in developed countries
worldwide. Interestingly, cancer prevalence is also increasing in developing areas of
the world as a result of population growth and aging as well as the adoption of riskfactor associated lifestyles (smoking, inactivity, “westernized” diets) [1, 2].
Breast cancer is the second most common cancer in the world and ranks number
one in terms of most frequent cancer diagnoses amongst women and the second
leading cause of cancer related deaths in North America [1-4]. Over the past 25 years
we have seen a drastic increase in overall 5-year survival rates for patients with breast
cancer, largely due to improvements in treatment and the widespread use of
mammography [5]. Breast cancer caught early on results in 5-year survival rates of
98.6% and 84.4% for localized and regional breast cancers, respectively [6].
However, survival rate significantly declines to less than 25% in women diagnosed
with late-stage metastatic spread [6, 7]. Therefore, the majority of deaths associated
with breast cancer are not due to the burden of the primary tumour, but rather the later
stages following metastatic spread, especially towards the lungs [8, 9].
The focus of this thesis is to investigate the importance of the native lung
microenvironment on the behaviour of both whole population and stem-like breast
cancer cells using an innovative 3D animal model, so we can better understand which
aspects of the lung make it a permissible environment for breast cancer to grow and
progress.
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2.

LITERATURE REVIEW

2.1.

Cancer
Cancer is a complex set of diseases characterized by the failure of cellular

growth regulation. Loss in regulation most often occurs by means of genetic
disruption, eventually resulting in loss of homeostasis and subsequent aberrant
growth and unlimited proliferative capacity. Fundamentally, characteristics acquired
during cancer growth and progression include self-sufficiency in growth signalling,
insensitivity to anti-growth signals, acquisition of limitless replicative capacity,
ability to promote and sustain angiogenesis, evasion of apoptosis and tissue invasion
and metastasis [10, 11].
Malignant transformation of normal cells can often be linked to disruptions in
two different categories of genes: oncogenes and tumour suppressor genes.
Oncogenes are those that promote cell growth and reproduction and are tumourpromoting when over stimulated. When constitutively activated, oncogenes cause
cells destined for apoptosis or cell death to survive and continue to proliferate [12]. In
contrast, tumour suppressor genes are those that inhibit cell division and survival and
promote apoptosis and cell cycle arrest [13]. Typically, mutations or epigenetic
changes in several genes are needed to transform a healthy cell into a malignant one
[14, 15].
Cancers are typically classified according to the cell type in which they
resemble and therefore most likely derive from. For example, carcinomas are cancers
derived from epithelial cells, sarcomas from connective tissue, lymphoma or
leukaemia from hematopoietic origin, germ-line tumours from germ-line cells and
blastomas from embryonic cells [16]. Benign tumours are those which remain
contained within the tissue of origin and are not usually life-threatening. In contrast,

!3

malignant tumours are life threatening and are able to invade surrounding tissues and
move to distant areas of the body separate from the primary tumour [12].
2.2.

Breast Cancer
The principle structure of the breast is the mammary gland. The mammary

gland is composed of alveoli lined with milk-producing cuboidal epithelia surrounded
by a layer of myoepithelia. Many alveoli join together to form groups called lobules,
each having a lactiferous duct responsible for draining to the nipple, composed of
ductal epithelia surrounded by myoepithelia [17, 18]. Breast cancer is neoplastic
formation originating from breast tissue, most commonly from the ducts that carry
milk or the lobules that supply them. The susceptibility of these structures to benign
and malignant transformations are in part a consequence of cycling hormonal
stimulation throughout life leading to increased cell turnover and accumulation of
genetic defects [19, 20].
Cancer originating from the milk ducts and lobules are referred to as ductal
carcinoma or lobular carcinoma, respectively [21]. Ductal carcinoma represents the
most commonly diagnosed breast tumour, accounting for approximately 75% of
breast cancer cases [22, 23]. Breast cancer can often be classified according to
different schemas. Histopathological analysis is commonly used when determining
the class of breast cancer. Tumours confined within the ducts or lobules that have not
spread beyond their borders are referred to as either ductal carcinoma in situ (DCIS)
or lobular carcinoma in situ (LCIS). Both DCIS and LCIS are non-invasive in nature
and lack invasion into surrounding tissues [24, 25]. Therefore, when breast cancer
remains in situ, traditional treatments are highly effective if required [26]. Prognosis
worsens for patients with invasive ductal or lobular carcinoma; characterized by
tumour that has infiltrated surrounding tissues [27]. Invasive disease often leads to
further cancer dissemination throughout the body, leading to distant metastatic
disease. Many of the traditional methods for treating breast cancer often fail once the
cancer has reached the metastatic setting [28]. Therefore, the majority of deaths
associated with breast cancer are attributed to cancer that has spread from the initial
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region of the breast to distant organs [8, 9], necessitating a deeper understanding of
this complex metastatic process.
2.3.

Breast Cancer Subtypes
In addition to histopathological classification, breast cancer can also be

categorized according to molecular subtype [22]. Genomic profiling and
immunohistochemical markers have revealed the presence of specific molecular
subtypes with predictable clinical behaviours. The Cancer Genome Atlas (TCGA)
classifies breast cancer subtypes into one of four specific groups: luminal A, luminal
B, HER2-enriched or basal-like (triple negative; TN) [29-31]. Although a complex
molecular and genetic profile is needed to determine exact subtype, most subtypes
can be roughly defined by hormone receptor status (estrogen and progesterone),
HER2/neu status (a member of the epidermal growth factor receptor family) and
proliferation rate [32, 33]. Luminal A tumours resemble the inner linings of mammary
ducts and tend to be ER+/PR+ and HER2-. Since these tumours are often ER+, they
respond well to hormone therapy and often have favourable prognoses and survival
rates associated with them [34, 35]. Luminal B tumours also resemble the inner
linings of mammary ducts and tend to be ER+/PR+ but are highly positive for the
proliferative marker Ki-67 and/or HER2+. Women diagnosed with these tumours also
tend to have fairly high survival rates, but not as high as those with luminal A
tumours [35, 36]. HER2-enriched tumours are most commonly ER-/PR- and HER2+,
although a small percentage of this subtype are HER2-. These tumours often have a
poorer prognosis and are prone to metastasis and frequent recurrence [31, 32, 37].
HER2+ tumours can however be treated with the targeted therapy Herceptin
(trastuzumab), which targets the HER2 surface receptor on breast cancer cells,
slowing growth and progression [38]. Basal-like or TN breast tumours share features
with the outer lining of mammary ducts and are defined as ER-/PR- and HER2-. Most
TN breast cancers are highly aggressive and have a poor prognosis and relatively low
5-year survival rates [32, 39, 40].
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Traditionally, molecular subtype classification has been involved with aiding
clinical treatment decisions for patients, particularly in terms of targeted therapies.
However, breast tumour populations are often heterogeneous in nature and therefore
are comprised of cells with varying molecular subtypes. Therefore, molecular subtype
classification should not be used exclusively as a means of treatment consideration,
especially as we continue to appreciate the vast heterogeneity that exists within solid
breast tumours [41]. !
2.4.

Metastasis
Metastasis is a complex process by which a series of cellular events are

ultimately responsible for tissue invasion and distant tumour establishment [42]. The
metastatic process consists of a series of coordinated steps in a prototypical cascade.
Over time, rare subsets of tumour cells acquire a more invasive phenotype and break
off from the primary tumour. Invasive tumour cells attach to basement membranes
and release extracellular matrix (ECM) degrading enzymes and factors, which
facilitate infiltration into surrounding tissues and entry into the circulation or
lymphatics [43]. As primary tumours grow and develop, they require a supply of
oxygen to support metabolic needs, and therefore promote angiogenesis or the
recruitment of new blood vessels. Angiogenesis and the proximity of a blood supply
to the tumour also provide a route by which tumour cells can invade the vasculature
and spread [28, 44]. Once in the circulation, tumour cells need to survive, which often
represents a rate limiting step for metastasis. Successful circulating tumour cells
(CTC) remain in the circulation until they extravasate into a new tissue where they
ultimately initiate and establish a secondary tumour, distant from the primary tumour
[28, 45, 46] (Figure 1). Metastasis is an inherently inefficient process as only a small
subset of invading tumour cells are able to successfully establish secondary tumours
and survive within the tissue [47]. Although this process is relatively inefficient, it
still remains one of the most important issues regarding cancer related deaths. Many
conventional anti-cancer therapies such as surgery, radiotherapy, and hormone
therapy are fairly successful when treating cancers detected and diagnosed prior to
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A. Primary tumour

B. Invasion

C. Dissemination
D. Extravasation

E. Secondary tumour
establishment

Figure 1. The metastatic cascade. Metastasis is a complex process by which tumour
cells spread to distant sites throughout the body. This occurs by a series of coordinated
cellular events: (A) Development of a primary tumour, (B) a subset of primary tumour
cells invade and enter surrounding tissue and vasculature, (C) tumour cells disseminate
within the blood and/or lymphatics, (D) tumour cells attach to vessel walls and
extravasate into a secondary tissue, (E) tumour cells establish a secondary tumour distant
from the primary tumour site. The final step represents a metastatic lesion.
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distant metastasis. However, most current therapies ultimately fail with respect to
metastatic tumours, for reasons still poorly understood [28]. Therefore, metastatic
progression illustrates a fundamental event for understanding during the progression
of cancer.
2.5.

Organ-specific Tropism
Although most cancers have the potential to spread to multiple organs, they

usually prefer certain sites in relation to others. The preference of particular cancers
to metastasize to specific organs is termed “organ tropism” and it has been well
established that breast cancer exhibits this phenomenon [28, 29, 48, 49]. Clinically,
the most common sites for breast cancer to spread to are the lung, bone, liver, brain
and lymph nodes (LN). Metastasis to the lung is of particular interest due to its poor
prognosis and lethality in breast cancer patients [29].
Multiple theories have been developed to explain the process of organ-specific
tropism, including Stephen Paget’s seminal “seed and soil” hypothesis in 1889, and
Ewing’s mechanical arrest theory [50]. Paget’s original theory suggested that organspecific patterns of metastasis are the result of favourable interactions between
tumour cells (the ‘seed’) and their respective organ microenvironment in the
secondary site (the ‘soil’) [51]. Paget’s theory therefore predicts that certain cancer
cells can survive and proliferate only in secondary sites that produce appropriate
factors to sustain growth and survival. In contrast, Ewing’s theory some forty years
later postulates that metastatic dissemination is strictly the result of mechanical
factors caused by the nature of the vascular system, meaning that cells are
mechanically arrested in the first capillary beds they encounter [52]. It is likely that
these two theories operate in concert rather than alone to produce and maintain
secondary tumour growth, as evidence has shown both theories hold true. That is,
breast cancer cells invade the local vasculature, are taken to the heart via the venous
circulation and subsequently delivered to the lungs where they mechanically arrest in
the first capillary beds they encounter. While there, successive initiation, growth and
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maintenance of secondary tumours within the lung is influenced, at least in part, by
specific lung-derived factors [53].
2.6.

Importance of Molecular Subtype
It is widely believed that as a result of genomic instability within tumour

populations, large-scale cellular heterogeneity develops in cancer. As a consequence,
tumour cell variants with augmented metastatic capabilities arise through selective
pressures [54-56]. Several studies have demonstrated specific genetic signatures or
molecular characteristics associated with organ-specific patterns of metastasis in
breast cancer [53]. As mentioned previously, breast cancers are often classified into
one of four major molecular subtypes (luminal A/B, HER2-enriched or TN) based on
genetic and immunohistochemical markers [29, 30]. One particular study by
Kennecke and colleagues examined the metastatic dissemination patterns for patients
with different breast cancer subtypes. Using 15-year cumulative incidence rates
according to metastatic site, they concluded that certain subtypes were associated
with particular patterns of metastatic spread. In particular, they found more aggressive
subtypes (HER2+ and TN) had a propensity for the lungs whereas less aggressive
subtypes preferred the bone as a metastatic site. Importantly, this disparity supports
the idea that certain molecular characteristics associated with breast cancer cells may
be involved in promoting organ-specific patterns of spread [29, 53].
2.7.

Breast Cancer Cell Gene Signature Can Influence Organ Tropism
In addition to specific patterns of metastatic spread based on molecular

subtype, work done by Joan Massagué’s group has also supported the notion that
molecular characteristics are in part responsible for organ-tropism. Their
experimental studies set out to determine a specific gene signature associated with
patterns of lung-specific metastasis in breast cancer. Using a mouse model of lung
metastasis, their group was able to successfully generate a lung-seeking variant of the
aggressive TN human breast cancer cell line MDA-MB-231 through multiple rounds
of in vivo selection [56]. Following transcriptome analysis of both parental and lungseeking variants, their work revealed a gene signature associated with lung-specific
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metastasis distinct from a previously identified bone-specific signature. Interestingly,
many genes identified had not been previously linked to metastasis. Genes that did
correlate with metastasis were comprised of extracellular and receptor proteins
including a HER receptor ligand (epiregulin; EREG), adhesion receptors (ROBO1),
specific chemokines (CXCL1), secreted proteases (MMP1), and transcriptional
regulator proteins (ID1, ID3) [45, 57, 58]. These important findings suggest an
intimate relationship between cancer cells, their genetic signature and specific organ
microenvironments most permissive to their growth and survival. However, it
remains relatively unclear as to when and why subsets of tumour cells acquire these
gene signatures during the progression of cancer.
2.8.

Stem-like Breast Cancer Cells
Recent studies have described a unique subpopulation of cancer cells within

solid tumours termed “cancer stem cells” (CSC) [59, 60]. These cells represent a
small subset of cells within the tumour characterized by stem-like properties
including self-renewal and multi-lineage differentiation [61]. The cancer stem cell
model suggests that CSCs represent a distinct population of tumour cells ultimately
responsible for tumour initiation, metastatic spread and therapy resistance [60]. The
first evidence to support this hypothesis was provided in 1994 by John Dick and
colleagues, who demonstrated that human acute myeloid leukemia (AML) was
organized as a hierarchy that originates from a primitive leukemia-initiating
hematopoietic cell [62, 63]. In breast cancer, tumour-initiating cells or CSCs have
been isolated from patient tumours and various breast cancer cell lines based on a
CD44+CD24- phenotype and/or high aldehyde dehydrogenase (ALDH) activity
[64-67]. CD44 is a cell surface glycoprotein with well-defined roles in cell-cell
interactions, cell adhesion, migration and metastasis [68]. The ALDH superfamily of
intracellular enzymes is involved in the detoxification of aldehydes [67, 69, 70] with
ALDH1A1 and ALDH3A1 isoforms having defined roles in normal stem cell
function and self-protection [71]. Interestingly, high expression of ALDH1 has been
associated with a poorer prognosis in breast cancer patients as well as an increased
risk of metastatic progression [72, 73]. Previous work done by Alysha Croker in our
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lab demonstrated that high ALDH activity in addition to CSC surface marker
expression (CD44+CD24-) selects for a highly enriched population of stem-like breast
cancer cells with enhanced metastatic properties and therapy resistance [67]. In this
study, ALDHhiCD44+ breast cancer cells isolated from MDA-MB-468 and MDAMB-231 breast cancer cell lines demonstrated enhanced cell growth, colony
formation, migration, and invasion in vitro as well as enhanced tumourigenicity and
metastasis in vivo [67]. This data demonstrates the functional importance of
ALDHhiCD44+ breast cancer cells in promoting many of the events that accompany
metastatic progression.
2.9.

The “Soil”: Organ Microenvironments
It is becoming increasingly clear that specific organ microenvironments have a

profound influence on the biology of tumour growth and survival. The end result of
the metastatic cascade (development of clinically relevant macrometastases) depends
greatly on the interactions between metastatic cells and host homeostatic mechanisms
[48, 57]. Previous studies have conclusively demonstrated in animal models that
tumour cells are able to reach the microvasculature of many organs but sustained
growth, survival and progression only occurred within specific organs [74, 75]. These
studies support the role of certain organ microenvironments in promoting and
sustaining metastases within a secondary environment. Once tumour cells reach
distant organs, they must proliferate to establish a successful secondary tumour. To
accomplish this, tumour cells can usurp physiological growth factors produced by the
microenvironment. In addition, the organ microenvironment can also influence how
metastases respond to common means of clinical intervention, including
chemotherapy and radiation [76]. For example, previous studies by Wilmanns et al.
have observed that murine fibrosarcomas or colon carcinomas grown subcutaneously
in syngeneic mice were sensitive to systemic administration of doxorubicin, whereas
lung or liver metastases were not [59]. Therefore, new therapeutic approaches for
metastasis should be targeted not only against tumour cells but also against host
factors favourable to tumour metastasis, growth, and survival.
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2.10.

Soluble Lung Microenvironment
Previous work done in our lab by Jenny Chu has led to the development and

establishment of a comprehensive ex vivo murine model for studying the influence of
organ-derived soluble factors on breast cancer cell metastatic behaviour. Organs
representing common clinical sites of breast cancer metastasis (lung, bone, liver,
brain, LN) were harvested from female nude mice and cultured for the purposes of
generating organ conditioned media (CM) [52]. Using this model, Chu demonstrated
that different human breast cancer cell lines show specific chemotactic and
proliferative behaviours in response to various organ-CM, reflective of their
metastatic behaviours in vivo [50, 53]. Specifically, the most aggressive of the cell
lines, MDA-MB-231, showed increased migration patterns towards bone, lymph
node, and lung-CM. The second most aggressive cell line, SUM159, displayed
enhanced migration towards the bone, brain, LN, and while the two least aggressive
cells lines (SUM149 and MDA-MB-468) demonstrated increased migration to lungCM only. More specifically, Chu’s work has also shown that stem-like ALDHhiCD44+
breast cancer cells exhibit preferential migration towards lung-CM over all other
organ conditions, complementing Croker’s previous work demonstrating that these
cells preferentially migrate to the lung in vivo [52, 67]. In addition to increased
migratory patterns, MDA-MB-231 and MDA-MB-468 cell lines demonstrated cell
line specific patterns of proliferation in response to organ-CM. MDA-MB-231 cells
showed increased proliferation in the presence of liver and lung-CM and MDAMB-468 cells showed increased proliferation in the presence of lung-CM [52]. These
results indicate the potential of the lung microenvironment in promoting metastatic
progression of breast cancer cells as demonstrated by enhanced patterns of migration
and proliferation in response to lung-CM.
Protein array analysis of lung-CM identified numerous soluble factors within
the lung microenvironment possibly contributing to breast cancer metastasis. Many of
these factors have implications during metastasis, migration, growth and adhesion.
One protein identified and of particular interest to our group is basic fibroblast growth
factor (bFGF or FGF-2) [52]. bFGF is one of 22 mitogenic members of the FGF
family, involved in wound healing, tissue repair, and embryonic development [77-79].
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Both low molecular weight (LMW) and high molecular weight (HMW) isoforms of
bFGF have been characterized, representing alternative translation products from a
single mRNA. The 18 kDa LMW isoform is primarily localized to the cytoplasm and
is the secreted form, whereas HMW (21-23 kDa) bFGF contains a nuclear
localization sequence (NLS)-like domain and is targeted to the nucleus [80-83]. Most
stimulatory effects induced by bFGF occur through the secreted LMW isoform and
canonically signal through the specific transmembrane fibroblast growth factor
receptors (FGFR). There are four tyrosine kinase FGF receptors (FGFR1-4), with
bFGF preferentially binding to FGFR1 or FGFR2 with higher affinity than FGFR3/4.
Non-canonically, bFGF also interacts and signals through alternative receptors,
including CD44 and vβ3 [77, 83].
bFGF has been implicated in cancer previously, as a proliferation-inducing
signal and during angiogenesis [81, 84, 85]. bFGF is of particular interest to us due to
its potent mitogenic capacity, as well as its ability to signal through the CD44
receptor, which is present on stem-like breast cancer cells [52, 67, 70]. However, its
role in the metastatic progression of breast cancer within the lung has not previously
been explored. This coupled with the fact that this protein has been previously
identified in our lab as a soluble factor present in lung-CM has led our interest as to
the influence of bFGF during metastatic progression of breast cancer in the lung.
2.11.

Insoluble Lung Microenvironment
The role of the lung microenvironment during cancer initiation and progression

is for a large part, poorly understood. The lung is composed of over 60 different cell
types involved in various functions including sensory, mechanical, secretory and
transport [86]. While the soluble microenvironment is much more intuitive to think of
as a contributor to cancer progression, we cannot disregard the influence the insoluble
microenvironment may play in this dynamic process. In the lung specifically, about
15% of alveolar tissue and 50% of non-alveolar tissue is noncellular, or ECM [87].
The ECM is composed of a myriad of structural proteins including collagen and
elastin, specialized proteins such as fibronectin and laminin, as well as high-
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molecular weight proteoglycans, which function to support surrounding parenchymal
cells [88-90].
Many types of epithelial and endothelial cells are dependent upon adhesion to
the ECM for their continued survival and often undergo apoptosis when this adhesion
is disrupted [91]. Although cancer cells are characterized by their unique ability to
progress and grow in the absence of ECM adhesion, solid tumours often exist in a
dynamic relationship between anchorage-dependence and independence [92]. One
potential implication of this is that tumour cells bound to the ECM may be relatively
protected from chemotherapy compared to non-adhered cells. Therefore, the insoluble
lung microenvironment in addition to soluble microenvironmental factors may have a
profound impact on the growth and therapy response patterns of cancer cells in the
lung.
2.12.

Techniques for Studying Metastasis in vivo
Traditionally, most metastasis-related research revolves around endpoint

analysis, e.g. after a detectable tumour has formed within a secondary site. While this
research sheds important light in terms of how and where tumours grow once they
metastasize, there often exists a lack of mechanistic knowledge as to how these cells
actually escape the primary tumour, invade and exit the vasculature, and ultimately
establish a secondary colony from the single cell stage. There exists a biological black
box during the metastatic progression from single tumour cells to the formation of
gross metastatic lesions [93]. Several attempts have been made to understand these
important initial steps of metastatic progression by imaging the early stages of
metastasis in vivo. Many of these modalities include techniques that mirror methods
for human imaging, including computer tomography (CT), micro-positron emission
tomography (PET), and magnetic resonance imaging (MRI) [94, 95]. However,
techniques also exist that lack a human correlate such as optical imaging (OI) of
bioluminescence (BLI) or fluorescence (intravital video microscopy; IVM). OI
represents a unique tool for whole body imaging in small animals. For example, BLIbased imaging has been used to monitor the development and progression of bone
metastases in living animals with a high degree of sensitivity [96, 97]. Similarly,
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IVM-based cellular imaging techniques are powerful tools for the continuous
monitoring of cellular processes in a living animal/tissue with a high degree of
resolution, something not currently possible with all OI techniques. IVM has been
used for measuring the heterogeneity within tumour populations and interactions
among subsets of cells within a tumour. It has provided tremendous insight into
various steps of metastasis including cell-cell interactions and the migration of cancer
cells [98]. Another potential method for understanding the cellular processes of
metastasis is in vivo video microscopy (IVVM). This provides a dynamic approach to
visualizing labelled tumour activity within the microcirculation in living animals [99]
and has provided valuable knowledge in terms of the inefficiency associated with the
metastatic process [100]. Findings using IVVM have shown that post-extravasation
growth of individual tumour cells contribute significantly to metastatic inefficiency
and not earlier steps in metastasis as once previously thought [101]. While these
techniques are certainly promising and can potentially uncover many key processes
underlying the process of metastatic progression, they are time consuming, often
require highly sophisticated and expensive imaging systems and do not allow serial
assessment at secondary sites [93, 95].
2.13.

Ex vivo Pulmonary Metastasis Assay
In 1992, Siminski and colleagues first established a method by which

pulmonary parenchyma could be maintained in serum-free conditions for up to 9
weeks. This unique ex vivo model system involved cutting murine whole lungs into
thin slices (~1-2 mm thick) and growing them in culture [102]. This model was later
adapted and modified by Mendoza et al. to study the influence of the lung
parenchyma on metastatic osteosarcoma, in an assay they described as a Pulmonary
Metastasis Assay (PuMA) [93]. The main advantage of this assay over traditional in
vitro techniques is that it recapitulates the native cellular and microenvironmental
complexity of the lung within the native 3D lung architecture. It allows valuable
insight into the progression of metastasis since cellular interactions between cancer
cells and both the lung parenchyma and ECM are maintained and can be
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experimentally investigated and/or targeted in an “open box” system, something not
always feasible in vivo.
2.14.

Study Rationale
Breast cancer remains the leading cause of cancer diagnosis and the second

leading cause of cancer-related deaths among women. If detected relatively early,
traditional therapies often prove highly effective. However, many conventional
therapies fail following the metastatic spread of breast cancer. Thus, the majority of
deaths associated with breast cancer are due to metastasis, and not the primary
tumour, particularly in patients with lung metastasis. Previous work in our lab has
demonstrated that stem-like ALDHhiCD44+ breast cancer cells display preferential
migration patterns towards lung-derived soluble factors and an increased propensity
to metastasize to the lung in vivo. However, the exact role of the lung
microenvironment in supporting growth and progression of breast cancer from a
single cells stage remains poorly understood.
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3.

HYPOTHESIS AND OBJECTIVES

3.1.

Hypothesis
Whole population breast cancer cells exhibit growth and progression within

an innovative ex vivo pulmonary metastasis (PuMA) model. More specifically, stemlike ALDHhiCD44+ breast cancer cells demonstrate increased growth and progression
from a single cell stage to micrometastases to macrometastases within the native lung
microenvironment in relation to their non stem-like ALDHloCD44- counterparts.
3.2.

Objectives

1. Establish a 3D ex vivo model system for investigating the role of the lung
microenvironment on breast cancer cell metastatic behaviour.
2. Evaluate the growth and progression patterns of whole population and
ALDHhiCD44+ breast cancer cells in the 3D model.
3. Determine the interaction between lung-derived soluble factor(s) and their
respective receptors on whole population and ALDHhiCD44+ breast cancer cells.
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4.

MATERIALS AND METHODS

4.1.

Cell Culture and Reagents
Commercial cell lines and culturing conditions are listed in Table 1.

Dulbecco’s Modified Eagle Medium/Nutrient Mixture F-12 (DMEM/F12),
HAM’S:F12, Modified Eagle Medium alpha ( MEM) used for cell culture and
Medium 199 (M199) used for culturing mouse lung tissue were purchased from
Invitrogen (Burlington, ON, Canada). Fetal bovine serum (FBS) was purchased from
Sigma (St. Louis, MO, USA). Tissue culture plates used were purchased from
NuncTM (Fisher Scientific, Ottawa, ON, Canada). Trypsin was purchased from
Invitrogen and used at a concentration of 0.25% in citrate saline. Ethylene diamine
tetraacetic acid (EDTA) was purchased from Bioshop Canada Inc. (Burlington, ON,
Canada) and used at a concentration of 1 mM in deionized water. Cells were cultured
and maintained under normal conditions of 37°C and 5% CO2 and used at low
passages.
4.1.1.

Generation of Fluorescent Cell Lines
Cell lines were generated to express tdTomato (excitation 554 nm, emission

581 nm). MDA-MB-468, SUM149 and MDA-MB-231 breast cancer cell lines were
transduced with lentivirus containing a tdTomato vector (pLVX-IRES-tdTomato), a
kind gift from Dr. Hon Sing Leong (London Health Sciences Centre). Stable
tdTomato-expressing cells were maintained in culture using puromycin (Invitrogen)
as a selection agent (0.25 μg/mL for MDA-MB-468 and SUM149, 0.5 μg/mL for
MDA-MB-231).

!18

Table 1. Cell lines and culturing conditions.
Cell line/Tissue

Culturing conditions

Source and References

SUM149

HAM’S F:12 + 5% FBS, 2.5 mL
insulin, 500 µL hydrocortisone,
5 mL HEPES

Asterand Inc. (Detroit,
MI, USA) [110]

SUM149tdTomato

HAM’S F:12 + 5% FBS, 2.5 mL
insulin, 500 µL hydrocortisone,
5 mL HEPES + 0.25 µg/mL
puromycin

Generated in-house

MDA-MB-231

DMEM:F12 + 10% FBS

American Type Culture
Collection (ATCC:
Manassas, VA, USA)
[108]

MDA-MB-231tdTomato

DMEM:F12 + 10% FBS + 0.5
µg/mL puromycin

Generated in-house

MDA-MB-468

MEM + 10% FBS

MD Anderson Cancer
Center (Houston, TX,
USA) [109]

MDA-MB-468tdTomato

MEM + 10% FBS + 0.25 µg/
mL puromycin

Generated in-house
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4.2.

Fluorescence Activated Cell Sorting
Fluorescence activated cell sorting (FACS) was used to isolate stem-like

ALDHhiCD44+ and non stem-like ALDHloCD44- subpopulations from both the MDAMB-231 and SUM149 breast cancer cell lines. The Aldefluor™ assay kit (StemCell
Technologies, Vancouver, BC, Canada) was used to assess ALDH activity in cellular
populations. The Aldefluor™ kit uses an uncharged fluorescent ALDH substrate
(BODIPY-aminoacetaldehyde (BAAA) that passively diffuses into cells. Cellular
ALDH activity converts uncharged BAAA molecules to negatively charged BAAmolecules, which prevents diffusion out of the cell. The trapped BAA- molecule
labels ALDHhi cells green. Cells are kept on ice prior to sorting to prevent the active
efflux of BAA- from labeled cells (Figure 2). Roughly 2 x 108 cells were harvested,
washed in PBS, centrifuged at 1000g for 5 min, and resuspended in assay buffer.
Suspended cells were incubated with Aldefluor substrate (1 µL BAAA/106 cells). A
control sample was also prepared in which diethylaminobenzaldehyde (DEAB; 1.5
mM), a specific ALDH inhibitor, was co-incubated with Aldefluor. DEAB allows
BAAA to remain in its uncharged form and therefore passively diffuse out of the cell.
During FACS analysis, ALDH+ cells were characterized based upon having higher
levels of fluorescence than the DEAB control. Both Aldefluor only and Aldefluor plus
DEAB samples were incubated for 50 minutes at 37°C. Following incubation,
samples were centrifuged (1000g for 5 min), resuspended with provided assay buffer
and labelled with a CD44-allophycocyanin (APC; BD Biosciences) antibody at 4°C
for 30 min. Cells were again centrifuged (1000g for 5 min) and resuspended in assay
buffer. Following resuspension, 7-aminoactinomycin D (7-AAD; BD Biosciences)
was added to sample tubes for monitoring of cell viability during FACS, and stored
on ice for immediate transport to the London Regional Flow Cytometry Facility for
FACS. To remove cellular clumping during transportation, cell suspensions were
filtered through a 70 µm mesh filter preceding FACS analysis. Sorting was
accomplished using a 4-colour analysis protocol on a FACSAria I or II (Bd
Biosciences) at the London Regional Flow Cytometry Facility. ALDH activity
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Figure 2. AldefluorTM Assay. The AldefluorTM assay is a fluorometric assay used to
detect human cells that express high levels of aldehyde dehydrogenase 1 (ALDH1). The
fluorescent neutrally charged BODIPY-aminoacetaldehyde (BAAA) molecule is taken up
by intact and viable cells by passive diffusion. In the presence of ALDH, BAAA is
converted into BODIPY-aminoacetate (BAA-) which is unable to diffuse out of the cell
due to its negative charge. Active removal of BAA- by ATP binding cassettes is inhibited
by the use of provided assay buffer and cold temperature (2-8°C). Resulting fluorescence
is proportional to ALDH activity and cells can be isolated using a cell sorter. A specific
inhibitor of ALDH, diethylaminobenzaldehyde (DEAB), is used to control for
background fluorescence. The population in the DEAB negative control provides an
appropriate gate for ALDHhi cells, whereby only cells demonstrating higher levels of
fluorescence than the DEAB control are included.
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was used as the primary sort criteria (ALDHhi = top 20%, ALDHlo = bottom 20%),
after which 50% of the ALDHhi cells were selected for the CD44+ phenotype and 50%
of the ALDHlo cells selected for the CD44- phenotype (Figures 3, 4). The resulting
isolated ALDHhiCD44+ and ALDHloCD44- populations were transported back to the
London Regional Cancer Centre and used immediately for injections in the PuMA
assay.
4.3.
4.3.1.

Pulmonary Metastasis Assay
Lung Seeding, Harvesting and Culturing
The pulmonary metastasis assay (PuMA) represents an innovative ex vivo

model for growing sections of lung in culture. This model allows real-time
assessment of metastatic progression, from single cells to micrometastatic to
macrometastatic colonies. A main advantage of this assay is that it provides the
unique ability to study the interactions between cells and the local host
microenvironment. Serum-free conditions are used for lung culture and were first
described by Siminski and colleagues [102] and later modified by Mendoza and
colleagues [93] (Table 2).
Healthy 5-7 week old female athymic nude mice (Hsd: Athymic NudeFoxn1nu; Harlan Sprague-Dawley, Indianapolis, IN) were purchased and maintained
under the guidelines of the Canadian Council of Animal care as outlined by the
protocol approved by the University of Western Ontario Council on Animal Care
(protocol #2009-064). TdTomato-expressing tumour cells were harvested, suspended
in either PBS (MDA-MB-468) or Hank’s Balanced Salt Solution (HBSS; Invitrogen)
(SUM149 and MDA-MB-231) and delivered by tail-vein injection to female athymic
nude mice. Within 15 minutes of cell injection, mice were euthanized by CO2
inhalation. Using sterile surgical conditions, the trachea was snipped and cannulated
with an 18G blunt needle. The lungs were infused under gravitational pressure with
1.2 mL of equal amounts of well-mixed lung medium 1/low melting agarose solution
(0.6%, 40°C). The trachea, lungs, and heart were carefully removed en bloc and
immediately placed in ice-cold PBS containing 100 U/ml penicillin and 100 µg/ml
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Figure 3. Isolation strategy for tdTomato expressing stem-like human breast cancer
cells from the SUM149 breast cancer cell line. Fluorescence activated cell sorting
(FACS) was used to isolate both ALDHhiCD44+ and ALDHloCD44- cell populations
labelled with 7-AAD, CD44-APC and the Aldefluor™ assay kit. Cell subsets were
isolated using a four-colour protocol on a FACS ARIA I or III and subsequently used for
the PuMA. (A) Cells were first selected based on expected light scatter, (B) viability
based on 7-AAD exclusion, (C) and tdTomato positivity. (D) Cells were further divided
into ALDHhi (top ~20% most positive of ALDH+ population) and ALDHlo (bottom ~20%
of ALDH+ population) populations. (E) Finally, cells were further selected based on a
CD44+ phenotype (~50% of the ALDHhi population), or (F) a CD44- phenotype (~50% of
the ALDHlo population). Resulting subsets were designated as either stem-like
(ALDHhiCD44+) or non stem-like (ALDHloCD44-) and were used immediately for
injection into the PuMA.
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Figure 4. Isolation strategy for tdTomato expressing stem-like breast cancer cells
from the MDA-MB-231 human breast cancer cell line. Fluorescence activated cell
sorting (FACS) was used to isolate both ALDHhiCD44+ and ALDHloCD44- cell
populations labelled with 7-AAD, CD44-APC and the Aldefluor™ assay kit. Cell subsets
were isolated using a four-colour protocol on a FACS ARIA I or III and subsequently
used for the PuMA. (A) Cells were first selected based on expected light scatter, (B)
viability based on 7-AAD exclusion, (C) and tdTomato positivity. (D) Cells were further
divided into ALDHhi (top ~20% most positive of ALDH+ population) and ALDHlo
(bottom ~20% of ALDH+ population) populations. (E) Finally, cells were further selected
based on a CD44+ phenotype (~50% of the ALDHhi population), or (F) a CD44phenotype (~50% of the ALDHlo population). Resulting subsets were designated as either
stem-like (ALDHhiCD44+) or non stem-like (ALDHloCD44-) and were used immediately
for injection into the PuMA.
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Table 2. Media formulations for lung tissue used in the PuMA.
Lung Media 1 (perfusion)

Lung Media 2 (culturing)

2X M199 Media

1X M199 Media

2.0 μg/mL bovine insulin

1.0 μg/mL bovine insulin

0.2 μg/mL hydrocortisone

0.1 μg/mL hydrocortisone

0.2 μg/mL retinyl acetate

0.1 μg/mL retinyl acetate

200 U/mL penicillin

100 U/mL penicillin

200 μg/mL streptomycin

100 μg/mL streptomycin

7.5% sodium bicarbonate

7.5% sodium bicarbonate
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streptomycin and stored at 4°C for 20 minutes to solidify the medium/agarose
solution within the lung. Transverse lung sections (1–2 mm in thickness) were cut
from each lobe using a scalpel blade. This typically gives 12–20 sections per lung.
Lung sections were carefully placed on a single sterile piece of Gelfoam (~1 cm x 1
cm) that had been preincubated for 1-2 hours in a 6-well plate with lung medium 2.
Lung sections were grown in culture for 21 days at 37°C in 5% CO2. Lung medium 2
was replaced every other day and lung tissue sections turned over carefully with
tweezers (Figure 5).
4.3.2.

Imaging and Analysis of Lung Sections
Seeded sections of lung were imaged at days 0, 7, 14 and 21 post-injection for

cancer cell growth and progression. Lung sections were first removed from culture on
their given day and fixed overnight in 10% buffered formalin phosphate (Fisher
Scientific) plus 25% sucrose (w/v) to preserve fluorescent signal. The following day,
sections were rinsed with PBS three times and carefully placed on a glass slide with a
glass coverslip gently sitting on top. Images were acquired using an upright Nikon
A1R confocal microscope at 20X objective (Nikon), with a 591 nm emission laser
(Melles Griot, Carlsbad, CA, USA). Three separate lung sections were imaged per
time point with five images taken per lung section. Growth and progression of
cellular populations within the lung was determined by measuring the mean
fluorescent area per field of view (FOV) for each section of lung (µm2) using ImageJ
software (NIH, Bethesda, WA, USA). Data were normalized to 1000 µm2 at day 0 to
account for variability in cellular delivery during tail-vein injection. Three mice were
injected for each cellular population with each replicate using cell populations from
different days.
To determine the relative degree of metastatic progression for each cell
population, we characterized the percentage of colonies present per image taken as
either single cells, micrometastatic lesions or macrometastatic lesions according to
measured diameter. We have set thresholds for single cells as 50 µm or smaller.
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Figure 5. Pulmonary Metastasis Assay (PuMA). The PuMA offers a real time
assessment of breast cancer cell growth from a single cell stage to multicellular colonies
in a metastatic setting. (A) Female nude mice are injected tail-vein with tdTomatoexpressing breast cancer cells. (B) Mice are sacrificed 15 min post injection by CO2
inhalation. The trachea is carefully cut and cannulated with an 18G blunt needle. The
lungs are infused with an agarose/lung media 1 solution using gravity perfusion. (C)
Lungs are carefully removed en bloc and cut into ~1 mm transverse sections. (D) Lung
sections are grown on Gelfoam® pre-incubated with Lung Media 2 and grown in culture
for 21-days. (E) Sections are removed from the PuMA at days 0, 7, 14 and 21 and fixed
in formalin for approximately 24 h prior to imaging. Sections are imaged for each time
point using confocal microscopy to determine metastatic growth, progression and colony
size.
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Traditionally, clinical micrometastases in breast carcinoma are defined anywhere
between 200 µm - 2 mm [103, 104]. We have therefore set the threshold for
micrometastatic lesions within the PuMA as being between 100-400 µm. There exists
much less consensus as to what clinically constitutes a macrometastatic lesion and as
a limitation to the size we can quantitatively measure in a given area of the images
acquired by confocal microscopy, we have set the threshold for macrometastases as
anything greater than 400 µm. Using the images taken for growth and progression
analysis for each time point, we determined the average proportion of colony sizes
per lung section using ImageJ software (NIH, Bethesda, MD, USA).
4.4.

Histology and Immunohistochemistry
Lung sections from the PuMA were fixed for at least 24 h in 10% buffered

formalin phosphate (Fisher Scientific), paraffin-embedded and sectioned at 5 µm on a
transverse plain. Hematoxylin and eosin (H&E) staining was carried out by Carl
Postenka (Histology Research Technician, London Health Sciences Centre). Masson’s
Trichrome Connective Tissue Stain kit was used according to the manufacturer's
instructions to evaluate muscle fibre and collagen presence within sections of lung
(Abcam, Cambridge, MA, USA). Expected Trichrome staining results were as
follows: collagen (blue), muscle fibres (red) and nuclei (black/blue).
Determination of proliferation competency within the PuMA was
accomplished using Ki-67 staining of seeded lung sections. Sections were rehydrated
in xylene followed by a series of graded ethanol incubations (100%, 95%, 80%,
70%). Sections underwent antigen retrieval in sodium citrate buffer (10 mM sodium
citrate, 0.05% Tween-20, pH 6.0) in a 100°C water bath for 20 min, then cooled at RT
for an additional 20 min. Staining was performed using the Mouse and Rabbit
Specific HRP/DAB (ABC) Detection Kit (Abcam) according to the manufacturer’s
instructions. Purified mouse monoclonal anti-Ki-67 antibody (1:75; Dako,
Burlington, ON, CA) was diluted in blocking buffer (1% BSA in PBS) and incubated
with tissue sections in a humid container O/N at 4°C. Detection of bFGF within
normal unseeded lung sections was accomplished using a rabbit polyclonal anti-FGF
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basic antibody (1:300; Abcam) which was diluted in blocking buffer (1% BSA in
PBS) and incubated with tissue sections in a humid container O/N at 4°C. Staining
was achieved using the same Mouse and Rabbit Specific HRP/DAB (ABC) Detection
Kit (Abcam). A negative antibody control (no primary) and negative tissue control
(mouse liver tissue) were used to rule out non-specific binding of primary antibody.
Following staining for Ki-67 and bFGF, tissues were dehydrated in a series of graded
ethanol (70%, 80%, 95%, 100%) ending in xylene, mounted with coverslips and
imaged using the Scanscope® CS System (Aperio, Vista, CA, USA).
4.5.
4.5.1.

Lung-Conditioned Media, Primary Cell Isolation and Reagents
Animals and Lung Harvesting
Healthy 5-7 week old female athymic nude mice (Hsd: Athymic Nude-

Foxn1nu; Harlan Sprague-Dawley, Indianapolis, IN) were purchased and maintained
under the guidelines of the Canadian Council of Animal care as outlined by the
protocol approved by the University of Western Ontario Council on Animal Care
(protocol #2009-064). Mice were euthanized by CO2 inhalation and their lungs
removed aseptically. The heart was carefully removed and the lungs were placed in a
pre-weighed 50 mL conical tube containing 30 mL PBS.
4.5.2.

Lung-Conditioned Media Generation
Following the harvesting of lungs (n=4 mice per session), the total weight of

lungs + PBS was determined using an electronic balance. Harvested lungs were
washed three times in ice cold PBS before being minced into ~1 mm3 fragments using
two sterile scalpel blades in a 60 mm2 glass petri dish. Lungs were weight-normalized
by re-suspension in a 4:1 media to tissue (v/w) ratio in DMEM:F12 supplemented
with Mito+ serum extender (1X; BD Biosciences, Mississauga, Canada) and
penicillin-streptomycin (50 U/mL penicillin-50 µg/mL streptomycin; Invitrogen).
Lung fragments and media were incubated at 37°C and 5% CO2 for 24 h. Following
incubation, conditioned media (CM) was removed from lung fragments, diluted by a
further three volumes of media and centrifuged at 1000g for 15 min to remove
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residual cell debris [43]. CM was filtered by a 0.22 µm syringe filter (Fisher
Scientific), aliquoted and stored at -80°C until use (Figure 6A).
4.6.

Assessment of bFGF Concentration
To measure the concentration of soluble bFGF in lung-CM, the Quantikine®

ELISA Mouse/Rat FGF Basic Kit was used (R&D Systems, Minneapolis, MN, USA).
Basal media, lung-CM and lung-CM depleted of bFGF were added to the supplied
pre-coated microplate and carried out according to the manufacturer's instructions to
measure the concentration of bFGF in lung-CM and the efficiency of bFGF
immunodepletion.
The Mouse/Rat FGF Basic Kit was also used to determine the concentration
of soluble bFGF secreted by normal unseeded lung tissue grown in the PuMA.
Surrounding media and Gelfoam® sections were collected for each time point (days
0, 7, 14, 21) and centrifuged at 1000g for 10 min to sediment the Gelfoam®. The
supernatant was collected and added to the microplate and carried through according
to the manufacturer's instructions to measure the concentration of soluble bFGF at
each time point throughout the assay. A standard curve was used for each experiment
and concentrations of bFGF were calculated using a four-parameter logistic (4-PL)
curve-fit software (elisaanalysis.com/app).
4.6.1.

bFGF Immunodepletion from Lung-Conditioned Media
To determine the influence of soluble bFGF on in vitro migration and

proliferation of breast cancer cells, bFGF was depleted from lung-CM using
Dynabeads® Protein G (Life Technologies). Lung-CM (1 mL) was added to a 1.5 mL
microfuge tube with 5 µL of neutralizing monoclonal bFGF antibody (1 mg/mL,
clone bFM-1; EMD Millipore, Etobicoke, ON, CA). The microfuge tube was inverted
twice and placed on a nutating mixer (VWR, Radnor, PA, USA) for 30 min at RT.
Following nutation, Dynabeads® were resuspended in the vial by vortexing for 30
sec. 50 µL (1.5 µg) Dynabeads® were transferred to a clean 1.5 mL microfuge tube
and placed in a magnetic rack (Invitrogen) for 2 min to separate beads from solution.
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Figure 6. Lung conditioned media generation and bFGF immunodepletion. (A)
Healthy female nude mice were euthanized by CO2 inhalation and their lungs removed
aseptically. Harvested lungs were washed, minced into ~1 mm3 fragments, and
resuspended in a 4:1 media to tissue (v/w) ratio for incubation at 37°C and 5% CO2 for 24
h. Following incubation, lung fragments were further diluted by three volumes of media,
centrifuged and CM filtered prior to use. (B) Immunodepletion of bFGF from lung-CM
was accomplished using magnetic Protein-G Dynabeads®. I. A neutralizing antibody
specific to bFGF was added to lung-CM. II. Lung-CM/bFGF antibody was mixed for 30
min whereby antibody bound free bFGF protein present in lung-CM. III. Lung-CM/bFGF
antibody mixture was added to magnetic Dynabeads® and mixed for 20 min. IV. After
mixing, a magnet was used to separate lung-CM from the bFGF antibody/Dynabeads®
mixture.
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The supernatant was carefully removed and 1 mL of lung-CM/bFGF antibody
mixture was added to the magnetic beads. The lung-CM/bFGF antibody/beads
solution was inverted twice and placed on a nutating mixer for 20 min at RT. After
mixing, the tube was placed in a magnetic rack for 2 min to separate lung-CM from
the bFGF antibody-beads mixture. Lung-CM depleted of bFGF was transferred to a
new tube and filtered by 0.22 µm syringe filtration (Fisher Scientific), aliquoted and
stored at -80°C until use (Figure 6B). For bFGF rescue experiments involving readdition of bFGF to immunodepleted lung-CM, recombinant bFGF (Sigma) at a
concentration of 0.3 µg/mL was added to depleted media prior to cell seeding. This
amount was equal to the concentration of bFGF determined to be present in normal
lung-CM.
4.7.

In vitro Transwell Migration Assay
Patterns of MDA-MB-231 and SUM149 whole population cellular migration

towards lung-CM were assessed using transwell migration assays. Prior the start of
the assay, 300 µL of gelatin (Bioshop) was warmed to 60°C for 20 min and further
diluted with 1500 µL of sterile water. Transwell inserts (24-well, 6.4 mm
polyethylene terephthalate membrane, 8 µm pore size; BD Falcon, Mississauga, ON,
CA) were then coated with diluted gelatin (6 µg/well) and allowed to dry at RT in a
sterile environment O/N. Immediately prior to the assay, gelatin was reconstituted
with control media (DMEM:F12 + Mito+ + 0.1% BSA; Bioshop) and agitated for 1.5
h at RT. Following reconstitution, SUM149 or MDA-MB-231 whole cell populations
were harvested, washed twice with PBS and suspended at a concentration of 5 x 105
cells/mL in control media. Excess media from the top of the transwells was carefully
removed with a pipette and 600 µL of negative basal media, lung-CM or lung-CM
depleted of bFGF was added to the bottom wells of a 24-well dish. Cells (5 x 104
cells/mL) were seeded onto the top portion of each transwell chamber. Chambers
containing cells were placed on top of the wells containing chemoattractant and
incubated for 18 h at 37°C, 5% CO2. Following incubation, transwell chambers were
removed, inverted and fixed with 1% gluteraldehyde (Fisher Scientific) in PBS for 20

!34

min. Fixed cells were washed with sterile water and 0.1% Triton-X-100 (Acros
Organics, NJ, USA) in PBS for 10 min. Cells were washed again with sterile water
and non-migrated cells were removed from the inner portion of the transwell chamber
with a cotton swab. Membranes were carefully cut out from the transwell chambers,
placed on a microscope slide and mounted with Vectashield with DAPI (Vector
Laboratories, Burlingame, CA, USA). Five high powered fields of view (FOV) were
captured for each well, and a mean number of migrated cells/FOV was calculated
using ImageJ software.
4.8.

In vitro BrdU Incorporation Assay
Proliferative responses of the human breast cancer cell lines SUM149 and

MDA-MB-231 to human lung-CM were assessed using a bromodeoxyuridine (BrdU)
incorporation assay. Whole population (1.5 x 104/well) were plated on 8-well
chamber slides (Lab-tek; Fisher Scientific) and allowed to adhere for 24 h, after
which cells were washed once with PBS and serum starved for 72 h. Media was then
replaced with lung-CM, negative control media (basal media; DMEM:F12 + Mito+),
or positive control media (DMEM:F12 + Mito+ + 10% FBS) for 24 h. Following
incubation, BrdU (5 µg/mL; Amersham Cell Proliferation Labelling Reagent; GE
Healthcare, Piscataway, NJ, USA) was added for 30 min. Following BrdU
incorporation, cells were washed with PBS and fixed with 10% neutral-buffered
formalin (Fisher Scientific) for 5 min. Cells were then incubated with 0.1% Triton
X-100 (Sigma) in PBS for 10 min to permeabilize cell membranes and subsequently
treated with 2N HCl (Fisher Scientific) for 10 min to denature DNA. Slides were
blocked for 30 min in 5% bovine serum albumin (BSA) in 0.1% Triton X-100 in PBS.
An anti-BrdU primary antibody (BD Biosciences) was added (1:75 dilution) in 5%
BSA/0.1% Triton X-100 in PBS for 1 h at RT. Slides were washed with PBS and a
FITC-conjugated anti-mouse IgG secondary antibody (H+L made in horse; Vector,
Burlington, ON, Canada) was added (1:100 dilution) in 5% BSA + 0.1% Triton
X-100 in PBS for 1 h at RT. Slides were washed with PBS to remove unbound
antibody, mounted with ProLong Gold with DAPI (Invitrogen) and allowed to cure
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O/N in the dark at RT. Images were taken (5 FOV/well) and nuclei counted using
ImageJ. Results were expressed as a percentage of BrdU positive cells to total nuclei.
4.9.

Blocking of bFGF and CD44 in the PuMA
To determine the effect of bFGF present within the lung microenvironment in

the context of the PuMA, antibody mediated blocking of either bFGF alone or its
non-canonical receptor, CD44 was used. Highly aggressive MDA-MB-231 breast
cancer cells were chosen as they were shown to progress to the greatest degree within
the PuMA. TdTomato-expressing MDA-MB-231 whole population cells were
harvested and first split into two groups: one group incubated at RT for 30 min in
HBSS and the other to incubate at RT in the presence of a rat monoclonal anti-CD44
antibody (1:50; Abcam) in HBSS for 30 min (Figure 7A). Following incubation, cells
were delivered to female nude mouse lungs by tail vein injection (5 x 105 cells/
mouse, n=3 mice) (Figure 7B). Lungs seeded with cells pre-incubated with an antiCD44 antibody were infused with the normal agarose/lung media 1 solution and
excised as per the PuMA protocol. Lungs seeded with cells not pre-incubated with
HBSS only were either infused with the normal agarose/lung media 1 solution or
agarose/media 1 solution plus a neutralizing monoclonal bFGF antibody (1:200, clone
bFM-1; EMD Millipore) before following the remainder of the PuMA protocol
(Figure 7C). Sections were cultured in serum-free conditions for 21 days, removed
from culture on their given day (0, 7, 14, 21) and fixed O/N in 10% buffered formalin
phosphate (Fisher Scientific) plus 25% sucrose (w/v) to preserve fluorescent signal.
The following day, sections were imaged for cancer cell growth and progression.
Three separate lung sections were imaged per time point with five images taken per
lung section. Growth and progression of cellular populations within the lung was
determined by measuring the mean fluorescent area per FOV for each section of lung
(µm2) using ImageJ software (NIH). Data were normalized to 1000 µm2 at day 0 to
account for variability in cellular delivery during tail-vein injection. Three mice were
injected for each experimental group using cell populations from different days.
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Figure 7. Blocking strategy for bFGF and CD44 in the PuMA. Both bFGF and CD44
were blocked to determine the effect of bFGF on breast cancer cell growth in the context
of the PuMA. (A) TdTomato-expressing MDA-MB-231 whole population cells were
harvested and either incubated in HBSS or incubated in the presence of an anti-CD44
antibody in HBSS. (B) Following incubation, cells were delivered female nude mouse
lungs by tail vein injection. (C) Lungs seeded with cells pre-incubated with an anti-CD44
antibody were infused with the normal agarose/media 1 solution. Lungs seeded with cells
not pre-incubated with an anti-CD44 body were either infused with the normal agarose/
media 1 solution or in agarose/media 1 solution plus a neutralizing bFGF antibody.
Resulting lungs were sliced into transverse sections and grown in culture according to the
PuMA.
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4.10.

Statistical Analysis
All experiments were performed using a minimum of three biological

replicates with internal triplicates, unless otherwise noted. Statistical analysis was
done using GraphPad Prism 6.0 (San Diego, CA, USA) and data are presented as
mean ± standard error of the mean (SEM). A one-way analysis of variance (ANOVA)
was used to compare data with multiple means and a two-way ANOVA used to
compare multiple means between different groups. Either a Dunnet’s, Tukey’s or
Bonferroni, or Sidak’s post-hoc test was used to confirm significance, as noted. Pvalues less than 0.05 were deemed statistically significant.
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5.

RESULTS

5.1.

Pulmonary Architecture Remains Structurally and Microscopically
Intact in the PuMA over 21 days
The PuMA represents an innovative model to study the behaviour of cancer

cells within the lung microenvironment in an open-box manner. We first wanted to
determine if sections of female nude mouse lungs could remain viable and healthy
throughout the duration of the PuMA. Unseeded slices of lung from healthy mice
were maintained according to the PuMA protocol. Lung slices were fixed, paraffin
embedded, sectioned and stained at days 0, 7, 14 and 21 with H&E for routine
histological examination and Masson’s Trichrome stain to evaluate connective tissue
components (Figure 8). H&E staining demonstrated that the lung remained
structurally intact with normal lung appearance throughout the 21 day period. Alveoli
were uniformly expanded throughout the lung for the duration of the assay with no
evidence of alveolar collapse. A thin outline of solidified agarose could be identified
within the alveoli and larger airways, which indicated successful infusion of the
agarose/media solution prior to the start of the PuMA. Alveoli, airways and large
vessels remained expanded with no evidence of collapse seen in the pulmonary
architecture. Both type I and type II pneumocytes were present at each time point
throughout the assay and could be appropriately identified. There was a decrease in
overall cellularity as evidenced by a qualitative reduction in total nuclei present at
days 14 and 21 compared to earlier time points. However, the overall lung
microarchitecture was remarkably unchanged throughout the duration of the assay
(Figure 8A). Sections of unseeded lung from the PuMA were also stained with
Masson’s Trichome stain to evaluate the presence of connective tissue during the
PuMA. Over the course of 21 days, muscle tissue was present surrounding arteries
and larger airways. Collagen fibres could also be identified at each time point and
were present surrounding vasculature. Although collagen was present throughout the
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Figure 8. Pulmonary architecture remains structurally and microscopically intact
in the PuMA over 21 days. To demonstrate the viability of the PuMA, normal unseeded
female mouse lungs were cultured according to the PuMA, fixed, paraffin embedded,
sectioned and stained. (A) H&E staining revealed the lung microarchitecture remained
relatively healthy and intact throughout the 21 day period. Alveoli (A), airways (B) and
large vessels (PA, pulmonary arteries; PV, pulmonary veins) throughout the lung
remained expanded and were of normal diameter. Overall, gross cellularity decreased at
days 14 and 21 compared to earlier time points. (Inset) Type I (blue arrows) and type II
(blue arrowheads) pneumocytes were present at each time point throughout the assay
and could be identified. Scale bar: 25 µm. (B) Masson’s Trichome stain was used to
evaluate connective tissue components in the lung. Over the course of 21 days, muscle
tissue (red stain) and collagen tissue (blue stain) remained visibly present with a slight
reduction in collagen staining at day 21. Each component was present and could be
identified at each time. Scale bars: 200 µm.
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duration of the assay, there appeared to be a slight reduction in collagen staining by
day 21 relative to earlier time points (Figure 8B). Each of these components was
present and could be identified at each time point.
5.2.

Whole Population MDA-MB-468, SUM149 and MDA-MB-231 Breast
Cancer Cell Lines Demonstrate Differential Growth Progression Within
the PuMA
To first determine the growth potential of whole population breast cancer cells

within the lung, we used three different breast cancer cell line models with varying
degrees of metastatic behaviour in vivo: very weakly metastatic MDA-MB-468,
weakly metastatic SUM149 and highly metastatic MDA-MB-231 breast cancer cells.
Cells were delivered to female nude mouse lungs by tail vein injection according to
the PuMA protocol. Sections were cultured in serum-free conditions for 14 days and
imaged at days 0, 7 and 14 using confocal microscopy to evaluate cellular growth and
progression. Only SUM149 and MDA-MB-231 cells demonstrated increased
fluorescence area at later time points compared to earlier time points (Figure 9B,C),
whereas very weakly metastatic MDA-MB-468 cells failed to progress into larger
colonies (Figure 9A). Highly metastatic MDA-MB-231 cells showed a greater
progression in growth area compared to the weakly metastatic SUM149 cell line.
Single cells could be seen in sections of lung in similar numbers at day 0 for each cell
line, demonstrating successful delivery of cells to the lungs. Single cells progressed
during the assay to small multicellular colonies by day 7 (SUM149, MDA-MB-231)
and even larger colonies by day 14 (MDA-MB-231). However, little to no growth
was observed for the very weakly metastatic MDA-MB-468 cell line over 14 days
(Figure 9B, C, D). Cellular growth of SUM149 cells indicated by fluorescent area
was significantly increased at day 7 (p≤0.05) and 14 (p≤0.001) relative to day 0, and
day 14 (p≤0.01) relative to day 7 (Figure 9E). Growth of MDA-MB-231 cells was
significantly increased at day 14 relative to days 7 (p≤0.05) and 0 (p≤0.01) (Figure
9F). Statistical significance was determined by one-way ANOVA with a Tukey’s post
test. Error bars represent ± SEM.

41

Figure 9. Whole population MDA-MB-468, SUM149 and MDA-MB-231 human
breast cancer cells differentially progress within the PuMA. To determine if breast
cancer cells were able to grow and progress within the PuMA, very weakly metastatic
MDA-MB-468, weakly metastatic SUM149 and highly metastatic MDA-MB-231 breast
cancer cells were injected (n=3 mice). (A, B, C) Representative images for each cell line
are shown. Five random images were taken for each of three lung sections for each time
point. Single cells are seen within the lung at day 0, which progress to multicellular
colonies by day 7 and 14 in the SUM149 and MDA-MB-231 populations only. Scale bars
represent 100 µm. A mean normalized fluorescent area (µm2) per image was measured
and averaged for each time point. (D) MDA-MB-468 cells fail to grow into larger
colonies. (E) SUM149 cell growth increased at day 7 (p≤0.05) and 14 (p≤0.001) relative
to day 0, and day 14 (p≤0.01) relative to day 7. (F) MDA-MB-231 cell growth increased
at day 14 relative to days 7 (p≤0.05) and 0 (p≤0.01). * indicates statistical significance.
Error bars represent ± SEM.
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5.3.

Highly Metastatic MDA-MB-231 Cells Proliferate in the PuMA
To assess the proliferative competency of breast cancer cells within the

PuMA, sections of lung seeded with highly metastatic MDA-MB-231 whole
population cells were fixed, sectioned and stained for the proliferative marker, Ki-67.
Positive Ki-67 staining was present at day 0 once cells had arrived to the lung and
throughout the duration of the assay (days 7, 14). Positive staining for Ki-67 was
most notable at day 14 in larger multicellular colonies (Figure 10B). Positive staining
was compared to a negative control (unseeded lung section from PuMA at day 14)
(Figure 10A). Serial sections from the same lung tissue from each time point were
also stained with H&E to confirm proliferative competency of breast cancer cells
(versus surrounding lung tissue). Indeed, H&E staining demonstrated a concentrated
presence of tumour cells corresponding to areas of Ki-67 positivity. Similar to Ki-67
staining, the most notable areas of tumour cells were seen in larger multicellular
colonies at day 14 relative to earlier time points (Figure 10C). To qualitatively
determine if these areas of tumour cells seen in seeded sections of lung were in fact
areas of tumour cells, seeded H&E sections were compared to an unseeded lung
section from the PuMA at day 14 (Figure 10A).
5.4.

Stem-like ALDHhiCD44+ MDA-MB-231 Breast Cancer Cells Progress
Relative to ALDHloCD44- Cells within the PuMA
After demonstrating the ability of whole breast cancer cell populations to

grow within the lung in the PuMA, we wanted to determine the growth differences
between stem-like and non stem-like breast cancer cells. To assess growth patterns of
weakly aggressive SUM149 and highly aggressive MDA-MB-231 cells, both cell
lines underwent FACS to isolate both stem-like ALDHhiCD44+ and non stem-like
ALDHloCD44- populations. Immediately following isolation, 5 x 105 ALDHhiCD44+
or ALDHloCD44- tdTomato-expressing SUM149 or MDA-MB-231 breast cancer cells
were delivered to female mouse lungs by tail vein injection (n=3 mice) and cultured
for 21 days following the PuMA protocol. Initial cellular delivery was similar for
both stem-like and non stem-like populations for each cell line injected. Single cells
were present within the lung at day 0 for both ALDHhiCD44+ and ALDHloCD44populations in each cell line. Weakly aggressive SUM149 ALDHhiCD44+ cells
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Figure 10. Highly metastatic MDA-MB-231 proliferate in the PuMA. To assess the
proliferative competency of breast cancer cells grown in the PuMA, both normal
unseeded and seeded sections of lung with highly aggressive MDA-MB-231 cells were
stained for the proliferative marker Ki-67. (A) Negative control for both Ki-67 and H&E
staining (unseeded lung section from day 14 in PuMA). (B) Seeded sections of lung with
highly aggressive MDA-MB-231 cells in the PuMA show positive staining for Ki-67 in
cells present in the lung at day 0 through day 14. Positive staining is most notable at day
14. (C) H&E staining of serial sections of seeded lungs confirmed proliferative
competency of highly metastatic cells within the PuMA, as seen with Ki-67 staining.
Scale bars represent 50 µm.
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Figure 11. Stem-like ALDHhiCD44+ MDA-MB-231 breast cancer cells progress
relative to ALDHloCD44- cells within the PuMA. To determine growth patterns
between stem-like and non stem-like breast cancer cells in the PuMA, ALDHhiCD44+ and
ALDHloCD44- cells were isolated by FACS from SUM149 and MDA-MB-231 human
breast cancer cell lines and injected into the PuMA (n=3 mice). (A, B) Representative
images for each population are shown. Five random images were taken per lung section
(n=3 lung sections) for each time point. Single cells are seen within the lung at day 0 for
both populations, which progress to increasingly larger multicellular colonies by day 21
only in the stem-like ALDHhiCD44+ population. Scale bars represent 100 µm. A mean
normalized fluorescent area (µm2) per FOV was measured and averaged for each time
point. (C) SUM149 cellular growth was increased in the ALDHhiCD44+ population
relative to the ALDHloCD44- population at day 14 (p≤0.05) and day 21 (p≤0.0001). (D)
MDA-MB-231 growth was increased in the ALDHhiCD44+ population compared to the
ALDHloCD44- population at day 14 (p≤0.001) and day 21 (p≤0.0001). * indicates
statistical significance between stem-like and non stem-like populations at a given time
point. Error bars represent ± SEM.
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progressed to small multicellular colonies by day 21, whereas non stem-like
ALDHloCD44- cells remained predominantly as single cells throughout the duration
of

the

assay

(Figure

11A).

Highly

aggressive

MDA-MB-231

stem-like

ALDHhiCD44+ cells progressed to much larger multicellular colonies by day 21
compared to non stem-like ALDHloCD44- cells which remained primarily as single
cells. Scale bars represent 100 μm (Figure 11B). SUM149 cellular growth increased
in the ALDHhiCD44+ population relative to the ALDHloCD44- population at day 14
(p≤0.05) and day 21 (p≤0.0001) (Figure 11C). Similarly, MDA-MB-231 cellular
growth increased in the ALDHhiCD44+ population compared to the ALDHloCD44population at day 14 (p≤0.001) and day 21 (p≤0.0001) (Figure 11D). Significance
between both populations at a given time point was determined by two-way ANOVA
with a Sidak’s post test. Error bars represent ± SEM.
5.5.

ALDHhiCD44+ Breast Cancer Cells Progress from Single Cells to
Micrometastases to Macrometastases in the PuMA while the Majority of
ALDHloCD44- Cells Remain as Single Cells
To further quantify the differences in progression within the lung between

stem-like ALDHhiCD44+ and non stem-like ALDHloCD44- breast cancer cells, we
measured and classified the size of colonies present in the PuMA. Three groups were
used to classify the sizes of multicellular colonies in the PuMA according to diameter:
diameter: single cells (≤50 µm), micrometastases (100-400 µm) or macrometastases
(>400 µm). Data were presented as a mean percentage of specific colony size (single
cells, micrometastases, or macrometastases) per image. Stem-like ALDHhiCD44+
cells from the weakly metastatic SUM149 cell line progressed from single cells at day
0 (100.0% ± 0.0 single cells, 0.0% ± 0.0 micrometastases, 0.0% ± 0.0
macrometastases) to micrometastases by day 21 (89.3% ± 4.7 single cells, 10.7 % ±
2.6 micrometastases, 0.0% ± 0.0 macrometastases). In contrast, the majority of non
stem-like ALDHloCD44- cells remained as single cells from day 0 (100.0% ± 0.0
single cells, 0.0% ± 0.0 micrometastases, 0.0% ± 0.0 macrometastases) throughout
the duration of the assay to day 21 (98.0% ± 2.0 single cells, 1.3% ± 1.3
micrometastases, 0.0% ± 0.0 macrometastases) (Figure 12A, Table 3). As predicted,
Highly aggressive MDA-MB-231 stem-like ALDHhiCD44+ cells grew to a greater

48

ALDHloCD44100

Single cells
Micromets 120
Macromets 100

80

80

Percentage of colonies
counted per FOV

120

Percentage of colonies
counted per FOV

SUM149

A

60
40
20
0

0

7

14

Single cells
Micromets
Macromets

60
40
20
0

21

ALDHhiCD44+

0

Day (post injection)

14

21

Day (post injection)

Single cells
Micrometastases
Macrometastases

B
100

Single cells
120
Micromets
Macromets 100

80

80

Percentage of colonies
counted per FOV

Percentage of colonies
counted per FOV

120

MDA-MB-231

7

60
40
20
0

40
20
0

0

7

14

Day (post injection)

21

Single ce
Micromet
Macrome

60

0

7

14

21

Day (post injection)

Figure 12. ALDHhiCD44+ breast cancer cells progress from single cells to micromets
to macromets while the majority of ALDHloCD44- cells remain as single cells.
Colonies present in lung sections grown in the PuMA were classified in diameter as
single cells (≤50 µm), micromets (100-400 µm) or macromets (>400 µm). Five random
images were taken per lung section (n=3 lung sections) for each time point. (A) Only
SUM149 ALDHhiCD44+ cells progressed from single cells at day 0 to micromets. (B)
MDA-MB-231 ALDHhiCD44+ cells progressed from single cells at day 0 through
micromets to macromets whereas ALDHloCD44- cells remained predominantly as single
cells.
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Table 3. Proportion of SUM149 ALDHhiCD44+ and ALDHloCD44- colony sizes in
the PuMA.
Day 0

Day 7

Day 14

Day 21

Single cells
(<50 µm)

100.0 ± 0.0
100.0 ± 0.0

98.7 ± 0.3
100.0 ± 0.0

95.7 ± 0.9
100.0 ± 0.0

89.3 ± 4.7
98.0 ± 2.0

Micromets
(100-400 µm)

0.0 ± 0.0
0.0 ± 0.0

1.3 ± 2.6
0.0 ± 0.0

4.3± 0.3
0.0 ± 0.0

10.7 ± 2.6
1.3 ± 1.3

Macromets
(>400 µm)

0.0 ± 0.0
0.0 ± 0.0

0.0 ± 0.0
0.0 ± 0.0

0.0 ± 0.0
0.0 ± 0.0

0.0 ± 0.0
0.0 ± 0.0

Bold Font = Stem-like ALDHhiCD44+ population
Regular Font = Non stem-like ALDHloCD44- population
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proportion of larger multicellular colonies compared to weakly aggressive SUM149
cells. MDA-MB-231 ALDHhiCD44+ cells progressed from single cells at day 0
(100.0% ± 0.0 single cells, 0.0% ± 0.0 micrometastases, 0.0% ± 0.0 macrometastases)
through micrometastases to macrometastases by day 21 (58.0% ± 2.0 single cells,
24.0% ± 2.2 micrometastases, 17.7% ± 4.3 macrometastases). Similar to patterns
observed with SUM149 cells, non stem-like MDA-MB-231 ALDHloCD44- cells
remained mainly as single cells throughout the duration of the assay. Single cells
present at day 0 (100.0% ± 0.0 single cells, 0.0% ± 0.0 micrometastases, 0.0% ± 0.0
macrometastases) progressed to few micrometastasis sized colonies by 21 (93.0% ±
2.5 single cells, 6.7% ± 2.9 micrometastases, 0.3% ± 0.3 macrometastases) (Figure
12B, Table 4). Overall, stem-like ALDHhiCD44+ cells isolated from both cell lines
progressed to larger sized colonies by day 21 faster and in greater numbers compared
to their non stem-like ALDHloCD44- counterparts.
5.6.

Basic Fibroblast Growth Factor is Present in Lung-conditioned Media
and Increases in vitro Breast Cancer Cell Proliferation, but not Migration
Previous work in our lab has identified the presence of many lung-derived

soluble factors present in the lung microenvironment that could potentially contribute
to the metastatic behaviour of breast cancer cells. Many of these soluble factors are
proteins that have well-characterized roles in cellular adhesion, migration and
neoplasia. In addition, many of the soluble factors identified in the lung are CD44associated proteins [52]. One specific protein of interest previously identified is basic
fibroblast growth factor (bFGF) due to its potent mitogenic effect, well-characterized
role in the maintenance of normal stem cells and its interaction with the cell surface
receptor, CD44 [83, 105]. Therefore, we wanted to determine the influence of bFGF
on breast cancer cell migration and proliferation. Conditioned media was generated
from healthy female mouse lungs, bFGF protein levels were assessed, and bFGF was
removed from lung CM by means of immunodepletion (Figure 13). bFGF protein
levels were determined by ELISA in basal media (BM), lung-CM, lung-CM exposed
to Dynabeads Protein G only, and lung-CM exposed to Dynabeads plus an anti-mouse
bFGF antibody. Data indicated that the concentration of bFGF present in lung-CM
was significantly higher than bFGF present in BM (p≤0.0001). Immunodepletion of
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Table 4. Proportion of MDA-MB-231 ALDHhiCD44+ and ALDHloCD44- colony sizes
in the PuMA.
Day 0

Day 7

Day 14

Day 21

Single cells
(<50 µm)

100.0 ± 0.0
100.0 ± 0.0

83.0 ± 4.0
98.7 ± 0.9

74.3 ± 1.5
96.0 ± 2.5

58.0 ± 2.5
93.0 ± 2.5

Micromets
(100-400 µm)

0.0 ± 0.0
0.0 ± 0.0

17.3 ± 3.8
1.3 ± 0.9

25.0 ± 1.2
4.0 ± 2.5

24.0 ± 2.2
6.7 ± 2.9

Macromets
(>400 µm)

0.0 ± 0.0
0.0 ± 0.0

0.0 ± 0.0
0.0 ± 0.0

0.7 ± 0.3
0.0 ± 0.0

17.7 ± 4.3
0.3 ± 0.3

Bold Font = Stem-like ALDHhiCD44+ population
Regular Font = Non stem-like ALDHloCD44- population
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bFGF was successful and resulted in lung-CM with significantly decreased bFGF
levels compared to lung-CM alone (p≤0.0001). These levels were in line with the BM
control. Dynabeads Protein G only in the absence of an anti-bFGF antibody had no
effect on bFGF depletion (Figure 13A). Data are presented as mean bFGF
concentration ± SEM (n = 3). To assess the influence of lung-derived bFGF on breast
cancer cell migration, whole population SUM149 or MDA-MB-231 cells were plated
in triplicate on top of gelatin-coated transwells. Transwells were placed in basal
media (DMEM:F12 + Mito+), normal lung-CM or lung-CM depleted of bFGF and
incubated for 18 hr at 37°C and 5% CO2. SUM149 cells showed a significantly
increased number of migrated cells exposed to lung-CM relative to BM (p≤0.01),
although this migration was not impacted by depletion of bFGF (Figure 13B). MDAMB-231 cells demonstrated a similar pattern to SUM149 cells with a significantly
increased number of migrated cells exposed to lung-CM relative to BM-, with no
influence of bFGF (p≤0.001) (Figure 13C).
To determine the influence of bFGF on cellular proliferation, SUM149 or MDAMB-231 cells were plated in triplicate in 8-well chamber slides and incubated for 24
hr at 37°C and 5% CO2 (n = 3) prior to incubation with BrdU. SUM149 cells showed
a significantly increased number of BrdU positive cells when exposed to lung-CM
relative to BM- (p≤0.0001), and this effect could be abrogated by depletion of bFGF
(p≤0.0001) to levels consistent with the BM- control (Figure 13D). MDA-MB-231
cells displayed similar BrdU incorporation patterns to SUM149 cells, with a
significantly increased number of BrdU positive cells exposed to lung-CM relative to
BM (p≤0.001) and abrogation of this effect with depletion of bFGF (p≤0.001) to
levels consistent with the BM control (Figure 13E). To determine if bFGF was in fact
increasing cellular proliferation, recombinant bFGF was added to immunodepleted
lung-CM. The re-addition of bFGF to immunodepleted lung-CM rescued the
reduction of cellular proliferation to levels consistent with non-depleted lung-CM.
This effect was apparent in both SUM149 and MDA-MB-231 cell lines.
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Figure 13. Depletion of bFGF from lung conditioned media reduces breast cancer
cell proliferation but not migration. To determine the effect of bFGF on breast cancer
cell migration and proliferation, bFGF was immunodepleted from lung-CM. (A) CM was
generated from healthy female mouse lungs and bFGF immunodepleted. Resulting bFGF
protein levels were determined by ELISA in basal media (BM), lung-CM, lung-CM
exposed to Dynabeads only, and lung-CM exposed to beads plus an anti-mouse bFGF
antibody. Data indicate bFGF is present in lung-CM and not in BM (p≤0.0001).
Immunodepletion of bFGF from lung-CM was successful (p≤0.0001). Data are presented
as mean bFGF concentration ± SEM (n = 3). (B, C) SUM149 and MDA-MB-231 cells
showed an increased number of migrated cells exposed to lung-CM relative to BM
(p≤0.01, p≤0.001). No migratory differences are seen for cells exposed to lung-CM
compared to lung-CM depleted of bFGF. (D, E) SUM149 and MDA-MB-231 cells show
a significantly increased number of BrdU positive cells exposed to lung-CM relative to
BM (p≤0.0001, p≤0.001). SUM149 and MDA-MB-231 cells exposed to lung-CM
depleted of bFGF (ΔbFGF) showed significantly less BrdU positive cells compared to
lung-CM (p≤0.0001, p≤0.001). Re-addition of recombinant bFGF to depleted lung-CM
(ΔbFGF/bFGF) rescued the effect on proliferation for both cell lines to levels consistent
with lung-CM alone. * indicates statistical significance. Data are presented as mean
number of migrated cells/FOV or percentage of BrdU positive cells per total cells
counted ± SEM (n = 3).
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5.7.

Basic Fibroblast Growth Factor is Present in the Intact Lung
Microenvironment
To further determine the presence of bFGF within the intact lung

microenvironment in the context of the PuMA, sections of normal unseeded lung
from healthy mice were immunohistochemically stained for bFGF at each time point
of the assay (days 0, 7, 14, 21) (Figure 14A). Sections of lung were grown in culture
according to the PuMA protocol, fixed, paraffin embedded and sectioned into 5 μm
slices for staining with an anti-mouse bFGF antibody. Unseeded sections of lung in
the PuMA consistently showed diffuse positive staining for bFGF at day 0 through
day 21. The highest levels of staining for bFGF corresponded to the basement
membrane surrounding vasculature within the lung. A negative control stained with
secondary antibody only was used to assess any non-specific binding of secondary
antibody. Furthermore, tissue from mouse liver was also used as a control to
determine if the anti-bFGF antibody simply bound to any tissue of mouse origin.
Staining shows that there is very weak signal for bFGF present in the liver whereas
signal in the lung is diffusely present throughout the tissue.
To further evaluate the presence of bFGF in the context of the PuMA, surrounding
media and Gelfoam® were collected for each time point in the PuMA on which
normal unseeded sections of lung were grown (Figure 14B). Media and Gelfoam®
were centrifuged together and the supernatant collected to measure the concentration
of secreted mouse bFGF by ELISA. Basal media (M199 media) alone contained no
soluble bFGF and day 0 contained negligible amounts of bFGF. By day 7, a small
amount of bFGF is present in the Gelfoam® and surrounding media. At days 14 and
21, this amount is more pronounced, with a significant increase in bFGF at day 14
relative to day 0 (p≤0.05) and media only (p≤0.05), and day 21 relative to day 0
(p≤0.05) and media alone (p≤0.05). This increase coincided with the length of time
that lung sections spent on the Gelfoam® throughout the duration of the PuMA.
Statistical significance at a given time point was determined by one-way ANOVA
with a Tukey’s post test. Data was presented as bFGF concentration (μg/mL) ± SEM.
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Figure 14. Basic fibroblast growth factor is present in the intact lung
microenvironment. To determine the presence of bFGF within the lung in the context of
the PuMA, sections of normal unseeded lung grown in the PuMA were
immunohistochemically stained for bFGF. (A) Unseeded sections of lung consistently
show diffuse positive staining for bFGF at days 0 through day 21. Positive staining is
most notable around the basement membranes of airways and vasculature (black arrow).
A antibody negative control consisted of the section stained with secondary antibody
only. Mouse liver tissue was used as a tissue control to determine the specificity of the
anti-bFGF antibody. Scale bars represent 200 µm. (B) Surrounding media/Gelfoam®
were collected for each time point in the PuMA which normal sections of lung were
grown. Basal media (BM) alone contained no soluble bFGF and day 0 contained
negligible amounts. By day 7, a small amount of bFGF is present in the Gelfoam and
surrounding media. At days 14 and 21, this amount is more pronounced with an increase
in bFGF at day 14 relative to day 0 (p≤0.05) and BM (p≤0.05), and day 21 relative to day
0 (p≤0.05) and BM (p≤0.05). * Indicates statistical significance. Data is presented as
bFGF concentration (µg/mL) ± SEM.

!57

5.8.

Blocking bFGF or CD44 on Whole Population MDA-MB-231 Cells Does
Not Decrease Cellular Growth in the PuMA
We next wanted to determine the influence of bFGF on cellular growth and

proliferation in the native lung microenvironment in the context of the PuMA. Using
the highly metastatic MDA-MB-231 whole cell population, cells were either preincubated with an anti-CD44 antibody in HBSS or in HBSS alone prior to injection.
Cells were then delivered to female nude mouse lungs by tail vein injection (5 x 105
cells/mouse, n=3 mice). Lungs seeded with cells pre-incubated with an anti-CD44
antibody were infused and excised as per the PuMA protocol (Figure 7). Lungs
seeded with cells pre-incubated with HBSS only were either infused with normal
agarose/media 1 solution or agarose/media 1 solution plus a neutralizing bFGF
antibody before following the remainder of the PuMA protocol. Sections were
cultured in serum-free conditions and imaged at days 0, 7, 14 and 21 using confocal
microscopy to evaluate cellular growth and progression. Following imaging, there
was a slight decrease in cellular growth and progression for bFGF blocked or CD44
blocked groups compared to normal seeded lungs by day 21 (Figure 15A,B,C). There
was a trend towards decrease in overall growth in the presence of a neutralizing bFGF
antibody or in cells pre-incubated with an anti-CD44 antibody at days 7, 14, and 21,
although this did not reach statistical significance (p>0.05) (Figure 15D).
Significance between experimental groups at a given time point was determined by
two-way ANOVA with a Sidak’s post test. Error bars represent ± SEM.
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Figure 15. Blocking bFGF and CD44 has no effect on growth reduction of whole
population MDA-MB-231 cells in the PuMA. To determine the influence of bFGF on
breast cancer growth in the context of the PuMA, both bFGF and one of its receptors on
breast cancer cells, CD44, were blocked. For bFGF blocking, cells were injected as per
the PuMA assay with the exception that lungs were infused with a neutralizing bFGF
antibody within the agarose/lung media 1 solution. For CD44 blocking, cells were preincubated with an anti-CD44 antibody prior to injection. The PuMA was carried out as
described above. (A,B,C) Representative images for normal seeded lungs, normal seeded
lungs infused with a neutralizing bFGF antibody and seeded lungs pre-incubated with an
anti-CD44 antibody. Scale bars represent 100 µm. A mean normalized fluorescent area
(µm2) per image was measured and averaged for each time point for each experimental
group. (D) A trend towards decrease in overall growth is seen for cells grown in the
presence of a neutralizing bFGF antibody or cells pre-incubated with an anti-CD44
antibody at days 7, 14, and 21, however this did not reach statistical significance
(p>0.05). Error bars represent ± SEM.
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6.

DISCUSSION
Breast cancer incidence has remained relatively constant over the past 10-15

years, with a general decline in the number of individuals succumbing to this type of
cancer. Despite the decreasing deaths rate associated with breast cancer, it still
represents the most frequently diagnosed cancer in women and the second leading
cause of all cancer related deaths in women in North America [2, 3, 106].
Research advances in the field of cancer have generated a wealth of
knowledge concerning how cancer initially develops and the potential targets worth
exploiting. However, as we gain a greater understanding of the complexities of both
the tumour and the tumour microenvironment, we are beginning to appreciate the vast
heterogeneity that exists within the tumour population. This in part has led to many
failed therapeutics and treatments in the metastatic setting, increasing the risk of
relapse and cancer recurrence in patients. It is therefore paramount that we put forth
efforts to better understand the mechanisms that determine why tumours spread in the
patterns they do and ultimately how this metastatic process occurs once single cells
reach secondary organs.
The lung is one of the most frequent sites of metastasis associated with breast
cancer, as a result of its large surface area and dense capillary network that make it
ideal for tumour cell stasis during circulation. Much work has been done investigating
the genetic signatures of breast cancer cells associated with specific patterns of
metastatic spread, specifically to the lung. This work, largely pioneered by Joan
Massagué and related groups, has increased our understanding of the the genetic
signatures that certain tumour cells acquire for lung-specific tropism [56]. However,
genetics alone do not account for patterns of metastatic spread, and we are beginning
to understand the profound influence of specific organ microenvironments and their
relationship with tumour development. It has remained a technical challenge to
understand the implications of both the soluble and insoluble microenvironments in
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secondary organs, particularly in the lung as they relate to metastatic progression.
Therefore, this study utilized a relatively new and innovative model system for
studying the influence of the lung microenvironment on breast cancer cells. The
pulmonary metastasis assay (PuMA) has allowed us to investigate the effect of both
the soluble and insoluble lung microenvironments on the behaviour of breast cancer
cells, specifically stem-like ALDHhiCD44+ cells, from the single cell stage to
multicellular colonies. This model will ultimately help elucidate how breast cancer
cells interact with the lung during metastatic progression and allow us to develop
methods of exploiting this microenvironment to limit growth and progression, with
hopes of eventual translation to the clinic.
We set forth to test the hypothesis that stem-like ALDHhiCD44+ breast cancer
cells demonstrate increased growth and progression from a single cell stage within
the PuMA compared to their non stem-like ALDHloCD44- counterpart. To our
knowledge, we are the first group to utilize this innovate ex vivo model system for
tracking the metastatic behaviour of stem-like breast cancer cells within the lung in
real time.
6.1.

Summary of Experimental Findings

1. An innovative ex vivo pulmonary metastasis assay (PuMA) was established in our
laboratory and demonstrated to maintain mouse lung viability and relevant lung
architecture in culture for 21 days, as reported by previous studies [93, 102].
2. Whole population MDA-MB-468, SUM149 and MDA-MB-231 breast cancer cell
lines differentially progressed within the PuMA with highly metastatic MDAMB-231 cells actively proliferating and showing the greatest degree of growth.
3. ALDHhiCD44+ breast cancer cells isolated from both SUM149 and MDAMB-231 human cell lines showed increased growth and progression from single
cells in the PuMA, relative to the non stem-like ALDHloCD44- population.
4. ALDHhiCD44+ breast cancer cells isolated from both SUM149 and MDAMB-231 cell lines progressed from single cells (≤50 μm in diameter) to
micrometastatic (100-400 μm) colonies within the PuMA, with MDA-MB-231
cells also progressing even further to macrometastatic colonies (>400 μm).
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5. Basic fibroblast growth factor (bFGF) was shown to be present in both lung-CM
and the intact lung microenvironment in the PuMA.
6. Depletion of bFGF from mouse lung-CM significantly reduced the proliferation
of both SUM149 and MDA-MB-231 cells in vitro, but had no effect on cellular
migration.
7. Blocking of either bFGF or its receptor CD44 did not significantly reduce cellular
growth and progression in the context of the PuMA.
6.2.

Advantages of the PuMA as a Model for Metastasis
Over 20 years ago, Siminski and colleagues successfully established a novel ex

vivo model system for studying the pathogenesis of lung injury. They required a
model system that accurately mimicked the in vivo environment of the lung, while at
the same time being simple and practical. With their model, they were able to
maintain normal pulmonary architecture and viability for up to 9 weeks in culture, in
serum free conditions [102]. It wasn’t until recently that this protocol was adapted to
model cancer metastasis in a secondary environment.
To accurately study the biology of metastasis, an optimal assay would
conveniently recapitulate the complexity of the cellular and non-cellular
microenvironment, while at the same time allowing a “glass window” to observe
metastatic progression. As a starting point, in vitro approaches are often employed.
These techniques are rarely sufficient in modelling the complex interactions that
occur between tumour cells and the host environment, both cellular and non-cellular.
To complement this, in vivo models, most often in mice, are required. However, these
models too often examine only the end-point of metastatic outcome (whether or not
secondary tumours have been established) and the time to late-stage metastatic events
[93, 107]. In order to bridge the gap between these traditional models of studying
metastasis, Mendoza et al. adapted the ex vivo model system first put forth by
Siminski some 20 years earlier. Their model, which they described as a pulmonary
metastasis assay (PuMA), was able to effectively discriminate between both weakly
and highly metastatic human and murine cancer cell lines that accurately modelled
their behaviour previously observed in vivo [93]. Their study therefore introduced a
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powerful tool for understanding the progression of metastasis in a secondary
environment.
We therefore utilized this innovative assay in order to better understand breast
cancer behaviour and metastatic progression in the context of the lung, a process
often associated with high rates of mortality. We were able to effectively demonstrate
that normal unseeded lung sections maintained in culture remained relatively healthy
and intact throughout the 21 day period. Important to this assay was that the gross
pulmonary architecture remained intact with no visible areas of collapse or loss of
structure with the presence of structural components (muscle tissue and collagen)
identified at each time point. Infusion of a 0.6% agarose solution prior to the
extraction of lungs was key to maintaining airways in an expanded state throughout
the duration of the assay. Other groups have demonstrated that without the inclusion
of agarose, lung architecture is almost completely lost within the first 24 hours in
culture [93]. In addition to intact pulmonary architecture, we have shown that
cellularity also remains in the lung during the assay. Using H&E staining, there is
evidence of cellular nuclei present throughout the lung at each time point of the assay.
More specifically, we were able to identify and distinguish between type I and type II
pneumocytes at the level of the alveoli at each time point throughout the assay.
Although there was an overall qualitative loss of cellularity within the lung at days 14
and 21 compared to earlier time points as expected [93], the lung microarchitecture
remained remarkably unchanged.
We next tested three breast cancer cell lines, each with varying degrees of
metastatic behaviour in vivo: very weakly metastatic MDA-MB-468, weakly
metastatic SUM149 and highly aggressive MDA-MB-231. Both MDA-MB-468 and
MDA-MB-231 cells were originally derived from the pleural effusions of patients
with breast cancer. In terms of molecular subtype, these cell lines are both classified
as triple negative (TN) and have a EGFR+/TGF +/ER-/PR-/HER2- phenotype [108,
109]. SUM149 cells were isolated from a patient with primary inflammatory breast
cancer. These cells bear a EGFR+/HER2,3+/HER4-/ER-/PR- phenotype [110]. Cell
lines demonstrated growth patterns that accurately paralleled their metastatic
behaviours in vivo. Previous studies have established the behaviours of these cell
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lines in vivo and although MDA-MB-468 whole population and stem-like cells
isolated based on an ALDHhiCD44+CD133+ phenotype have produced lung tumours
in mice injected by tail-vein, their mean metastatic burden (percentage of total lung)
was quite low (<1%), indicating an inability of these cells to progress to
macrometastatic colonies. Conversely, whole population and ALDHhiCD44+CD24stem-like MDA-MB-231 cells have produced a much higher metastatic burden within
the lung (>15%) and consistently produce macrometastases [52, 67]. Therefore, it’s
not surprising the MDA-MB-468 cell line produced the smallest degree of growth
within the PuMA relative to the more aggressive SUM149 and MDA-MB-231 cell
lines. Results of this study therefore validate this model as an effective surrogate for
studying in vivo breast cancer metastasis. The PuMA provides an advantage over both
in vitro and in vivo techniques for studying metastasis. Cells often behave quite
differently when cultured on plastic compared to a native environment. For example,
in one particular study, lung cancer cells grown in 2D tissue culture expressed
significantly lower levels of MMP-1, 9, 10 and no expression of MMP-9 compared to
the same cells grown in a native 3D lung matrix maintained in a bioreactor [111].
Therefore, the PuMA provides a more biologically relevant way for studying the
behaviour of breast cancer within a secondary environment, something not always
feasible with in vitro studies. Furthermore, the PuMA allows for the possibility of
real-time assessment of metastatic progression at multiple time points using a single
mouse lung. To accomplish this in vivo would require a vast number of mice as well
as investigator time. In addition, studying metastatic progression from the single cell
level is rarely achievable in vivo due to resolution limitations with current imaging
techniques. Therefore, in this regard, the ex vivo PuMA provides a more efficient and
cost effective strategy for evaluating metastatic progression in a native environment
and allows for studying the behaviour of breast cancer from a single cell stage once
cells have immediately reached the lung.
6.3.

ALDHhiCD44+ Breast Cancer Cells Drive Metastatic Progression Within
the Lung Microenvironment
Evidence within the literature suggests that only a small subset of cells are able

to successfully navigate the metastatic cascade to eventually initiate and form

!65

secondary metastases. It has therefore been postulated that cancer stem cells (CSC) or
stem-like cancer cells represent the subset of tumour cells responsible for metastatic
disease [61, 112]. In breast cancer, the population of CSCs are traditionally isolated
based on both surface markers (CD44+CD24-) and functional activity (ALDHhi). The
utilization of both functional activity in addition to surface markers increases the
validity of isolation due to the inherent heterogeneity of tumour cell surface marker
expression as a result of genetic instability [67, 113-115]. In this study, we isolated
stem-like breast cancer cell populations using a two marker strategy. Therefore, we
isolated stem-like cells using ALDH as a primary sort criteria and CD44 expression
as secondary sort criteria. Previous studies have shown similar functional metastatic
capabilities between cells isolated using an ALDHhiCD44+ approach versus cells
isolated using ALDHhiCD44+CD24- [65, 67], and we therefore did not include CD24
in our cell sorting criteria. Therefore, we are confident that the cells isolated from
both cell lines used in this study represent the most aggressive and metastatic
population.
Our specific interests relate to understanding the contribution of ALDHhiCD44+
breast cancer cells during the process of metastasis, and how the lung
microenvironment ultimately interacts with these cells to promote metastases
formation once these cells immediately reach the lung. Although there is a wealth of
knowledge concerning the existence of stem-like cancer cells in primary tumours,
much less is known regarding the functional and mechanistic implications of these
cells in mediating metastasis. Using the PuMA, we have evaluated the growth and
progression patterns for both stem-like and non stem-like breast cancer cells within
the native lung microenvironment. We have observed that breast cancer cell
populations isolated based on an ALDHhiCD44+ phenotype demonstrate increased
growth over the course of 21 days compared to ALDHloCD44- cells. Moreover, stemlike ALDHhiCD44+ progressed within the PuMA from single cells once delivered to
the lungs, to micrometastases (SUM149, MDA-MB-231) to macrometastases (MDAMB-231), whereas the majority of non stem-like cells in both cell lines remained
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predominantly as single cells, showing very little progression to the micrometastases
stage, if any. Together these results indicate that breast cancer cells, specifically the
stem-like ALDHhiCD44+ population, are responsible for metastatic progression within
the lung. Differences in growth are not a result of a discrepancy in cellular delivery,
since a similar number of both ALDHhiCD44+ and ALDHloCD44- cells are able to
reach the lungs initially at day 0. Therefore, it is specifically the stem-like population
that is able to interact with the native lung microarchitecture to successfully establish
secondary tumour populations, whereas the majority of non stem-like cells remain as
single cells and fail to progress past the micrometastases stage. Importantly, the
PuMA assay has allowed us to dissect out the role of the lung microenvironment in
mediating the 2 most significant rate-limiting steps in metastasis (and those we
hypothesize to be facilitated by stem-like cells): the transition from single cells to
micrometastases, and from micrometastases to macrometastases [116, 117]. This is
very difficult to do in real-time using in vivo models, since most imaging technologies
do not have this degree of sensitivity, particularly in the lung.
6.4.

The Complexity of the Lung Microenvironment
The microenvironment of organs is comprised of normal parenchymal cells,

stromal cells and insoluble elements including the ECM and ECM-related factors as
well as soluble factors [118]. We are beginning to appreciate how certain organ
microenvironments can influence the biology of tumour growth and survival, a
concept that’s relatively new in the field of metastasis. As stated by Fidler in a review
of the organ microenvironment and metastasis, the extent of tumour cell proliferation,
invasion, angiogenesis and survival are in part determined by the specific organ
microenvironment [48].
The lung microenvironment is no exception to this complexity. The lung is
composed of a dense vascular network, surrounded by over 60 different cellular types
including cells with sensory, secretory, mechanical and transport functions [119], each
with distinct expression patterns for soluble factors. Moreover, the insoluble ECM
and ECM-related components of the lung function as a scaffold for these cells.
Therefore, there are many potential sources in the lung microenvironment that may
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contribute to the metastatic behaviour of breast cancer cells once they reach the lung.
Together, these factors probably do not influence the behaviour of breast cancer
exclusively but rather, many of these components likely act together to drive the
process of breast cancer metastasis within the lung. Previous work done in our lab has
focused primarily on the soluble component of the lung microenvironment and thus
was used as a potential target in this study.
Work done by Jenny Chu has identified over 70 soluble factors within the lung
microenvironement that may be contributing to the growth and metastatic behaviour
of breast cancer once they reach the lung [52]. This work predominantly concentrated
on the soluble lung microenvironment and its role as a chemoattractant for breast
cancer cells. Her work demonstrated that soluble factors within lung-CM including
the CD44 ligands osteopontin (OPN) and L-selectin (SELP) mediated breast cancer
cell migration in vitro [52]. Although her work led to a greater understanding of the
contribution of the soluble lung microenvironment to the “getting there” stage of
breast cancer metastasis, much less has been explored in terms of the “growing there”
portion of breast cancer metastatic progression. One of the proteins previously
identified within lung-CM and of particular interest to us was bFGF.
6.5.

bFGF in the Lung Microenvironment
We were especially interested in the role of soluble bFGF and its influence on

breast cancer cell metastatic behaviour and progression within the lung, particularly
in the context of the ex vivo PuMA. bFGF is well known for its potent mitogenic
effects, with many of its pro-proliferative activity linked to promoting growth and
proliferation in primary precursor cells [120]. Coupled with the fact that this
particular protein is involved in the maintenance of self-renewal in stem cells and
often found in media for culturing stem cells [121], we sought to determine its
influence on breast cancer cell behaviour both in vitro and in the PuMA. Therefore,
bFGF represented an appropriate target worth exploring within the lung
microenvironment especially since murine and human bFGF share a 97% amino acid
sequence identity (UniProtKB/Swiss-Prot-P09038).
Using our previously described ex vivo murine model system for generating
organ conditioned media [52], we were able to show that bFGF present in mouse

!68

lung-CM increased the proliferation of both SUM149 and MDA-MB-231 whole cell
populations as assessed by BrdU incorporation. Moreover, this increase in
proliferative behaviour was abrogated following the immunodepletion of bFGF from
lung-CM and could be rescued by re-introducing recombinant bFGF to
immunodepleted media. Interestingly, we observed a lack of migratory responses
towards bFGF using Transwell migration assays which indicated that this protein was
more important for promoting proliferation versus migration of breast cancer cells.
Taken together, these results suggest that bFGF may play more of a role in the
“growing there” versus “getting there” stage of breast cancer metastasis. Although
bFGF has previously been characterized as a chemoattractant, most of these studies
have been in the context of evaluating the process of angiogenesis, using endothelial
cell lines, not breast cancer cells [122].
Following in vitro experiments suggesting the role of bFGF in promoting
proliferation of breast cancer cells, we aimed to target this protein in the PuMA to
determine if we could interfere with breast cancer cell growth and progression. We
chose to evaluate the response of highly metastatic MDA-MB-231 whole population
cells due to their prominent growth observed in the PuMA compared to the other cell
lines (MDA-MB-468 and SUM149). We first demonstrated the presence of bFGF in
the intact lung used within the PuMA. Immunohistochemical staining for bFGF
revealed a diffuse pattern of staining throughout the lung, with a high degree of
positive staining surrounding vasculature. This pattern of staining was expected as
bFGF is normally expressed ubiquitously and present in high amounts in the
basement membranes and ECM of blood vessels [123]. We were also able to show
that bFGF was present within the Gelfoam® that lung sections were grown on during
the PuMA. Over the course of 21 days, there was an increase in the amount of bFGF
detected at later time points, compared to earlier ones. This increase coincided with
the length of time that lung sections spent on the Gelfoam® throughout the assay.
Despite the changing of media every other day, an increase in concentration was still
observed suggesting that bFGF was continuously secreted by the sections of lung
grown on Gelfoam® and that secreted bFGF remained bound or stuck within the
network of the Gelfoam®.
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To determine the effect of bFGF in the ex vivo PuMA, we utilized antibodymediated blocking of both mouse bFGF produced in the lung and CD44, a noncanonical bFGF receptor present on breast cancer cells. Although no significant
reduction in breast cancer growth in the lung was observed, data indicated a general
trend towards a reduction in growth of MDA-MB-231 cells. Due to the difficulty of
blocking these proteins continuously over the course of 21 days, the negative results
may be due to technical challenges rather than a lack of biological response. First,
lung sections, although thin (~1 mm), still represent a significant area for penetration
of antibody during the assay. Therefore, simply adding fresh antibody throughout the
assay would not increase the exposure between antibody and tumour cells. Therefore,
we opted to instead perfuse the lung with a mouse-specific neutralizing bFGF
antibody prior to the removal of lungs from mice and pre-incubated cells with an antiCD44 antibody prior to tail-vein injection. For bFGF blocking in the PuMA, we
chose to use a concentration of antibody equal to the amount needed to successfully
deplete lung-CM. Therefore, another potential source of negative response may be
due to an ineffective concentration of neutralizing bFGF antibody initially used when
perfusing the lung, or a diminishing biochemical activity of bFGF antibody
throughout the assay. Unfortunately, there is very little data within the literature to
suggest an appropriate starting point for antibody-mediated blocking using the PuMA
since this is a relatively new model. Work that has been done regarding targeting
within the PuMA is primarily focused on testing chemotherapeutics and not
antibodies [93]. For CD44 blocking, cells were pre-incubated with an anti-CD44
antibody prior to injection. Therefore, a negative reduction in growth associated with
blocked CD44 may indicate the antibody does not remain bound during the initial
seeding to the lung or a diminishing biological activity throughout the assay. Another
possible explanation is that breast cancer cells are able to compensate for decreased
CD44 receptor activity in relation to bFGF by using its canonical receptor (FGFR1),
normally expressed by MDA-MB-231 cells [85] or other receptors involved with
fine-tuning bFGF signalling (integrin

vβ3, heparin, thrombospondin, fibrinogen,

PDGF) [83]. Ultimately, more work needs to be done with regards to optimization of
antibody-mediated blocking techniques within the PuMA before we can confidently
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rule out bFGF as a potential target within the native lung microenvironment that
could reduce the metastatic behaviour of breast cancer cells.
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7.

POSSIBLE LIMITATIONS OF THE STUDY

Findings and subsequent conclusions made in this study are based upon
certain assumptions, particularly concerning features of the presented ex vivo models.
The PuMA represents an innovative model system for assessing growth and
progression of cancer cells in real time within a native lung environment. While this
model illustrates a promising approach for studying breast cancer metastasis in a
secondary environment, like most models, it is not without its limitations.
The first assumption is that breast cancer cell growth and progression in the
PuMA is not influenced by the immune system. This study utilized athymic NudeFoxn1nu mice which have an inhibited immune capacity due to a reduced number of
mature T-cells. Because of this, they are unable to mount adaptive immune responses
and are therefore ideal for studying the growth of solid tumours derived from humans
[124]. Nude mice were also chosen to compare current and future results with
previous in vivo findings using this mouse strain. In addition, in context of the PuMA,
due to the excision of the lungs from nude mice and subsequent slicing of the lung,
there is no active immune system regardless. While in theory, the advantage of the
PuMA is that it accurately represents the pulmonary architecture that breast cancer
cells would encounter physiologically, it still does not take into account the
contribution

and

possible

interaction

of

the

immune

system

during

immunosurveillance of tumour cells.
The second assumption is that murine secreted factors and insoluble matrix
components interact with human cancer cells both in the PuMA and lung-CM.
Traditionally, murine models are utilized because they are small, easy to handle and
have consistent disease manifestations. More importantly, mice have over a 95%
similarity to human genetics, with many genes showing high degrees of conservation
between the two species. Despite the significant evolutionary genetic conservation
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between mice and humans, certain ligand-receptor interactions may remain
incompatible between the two species. However, many secreted murine factors are
still able to stimulate cellular responses in human cells [125]. Ethically speaking, the
collection of human lungs in lieu of murine lungs presents a challenge and is not
feasible, thus the murine model system was both practical and essential.
The third assumption in terms of the ex vivo lung-CM model system is that
lung-derived soluble factors are adequate for inducing changes in cellular behaviour,
particularly migration and proliferation. In reality, the metastatic niche is composed
of insoluble factors, ECM components and various cell types in addition to soluble
factors. All of these factors can potentially contribute to tumour cell behaviour.
Although, changes in cellular proliferation were seen in this study, results would have
been strengthened with the addition of the ECM or ECM-related components to the
assay outlined above.
Finally, as with most basic science cancer research, these studies relied on
immortalized human cell lines rather than primary human breast cancer cells. While
immortalized cells used in this study originated from primary patient samples, they
have undergone significant mutations to become immortal. In addition, there still
represents the potential for these cell lines to acquire additional mutations due to
failures in DNA repair. Although immortalized cell lines are easy to obtain and
maintain in culture, they still may not accurately represent the true behaviour present
with primary patient-derived breast cancer cells.
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8.

FUTURE DIRECTIONS

As mentioned previously, the occurrence of lung metastases in breast cancer
patients is often associated with high rates of mortality. This highlights the
importance of understanding the contribution of the lung microenvironment as a
whole in mediating lung related metastatic spread. Therefore, elucidating specific
factors or signals involved in promoting lung specific tropism in breast cancer should
remain a strong focus.
The molecular basis for organ-specific metastasis has started to gain
significant attention amongst the scientific community, especially as we continue to
discover the disparity between the behaviour of primary tumour cells and those in the
metastatic setting. Traditionally, metastasis-related research tends to focus more on
the end point, e.g. after a clinically detectable tumour has developed. This approach
often overlooks the importance of the initial steps of tumour establishment and
subsequent metastatic progression. One of the main advantages of the PuMA is that it
shifts the focus from the end point of metastatic development by also incorporating
the initial stages of metastatic progression. Therefore, future work should centre
around determining aspects of the lung microenvironment responsible for promoting
successful micrometastases development. This study in particular focuses on one
soluble factor specifically, bFGF. Methods in addition to antibody-mediated targeting
of bFGF, such as small molecule inhibitors should be utilized to determine the full
extent of bFGF influence on breast cancer cell behaviour. For example, the chemical
SSR128129E has been shown to effectively inhibit bFGF signalling by binding to the
extracellular domain of FGFR receptors [126-128]. Additionally, selective FGFR1/3
small molecule inhibitors including PD173074 [129-131], and FGFR1 inhibitors
including PD161570 [132, 133] also exist and provide another possible route of
inhibition. These small molecule inhibitors have been used both in vitro and in vivo
and show promise for decreasing the growth of certain cancers. However, these
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molecular inhibitors have not been used in the context of either breast cancer or breast
cancer metastasis, and thus provide encouraging methods for inhibiting bFGF within
the PuMA. To further complement blocking of bFGF within the PuMA, future work
in assessing bFGF could be better suited using a systemic bFGF knockout mouse
model. The Fgf2tm3Doe/Fgf2tm3Doe mouse model provides a unique approach for
evaluating the behaviour of breast cancer cells in an environment devoid of bFGF.
These mice develop and age normally with a normal lifespan and exhibit regular
organ architecture [134]. Therefore, these mice could be used in the context of the
PuMA outlined above using syngeneic mouse breast cancer cell lines. Comparisons to
mice with normal bFGF expression or to bFGF knockout mice with re-introduced
bFGF (added to the infused agarose/media 1 solution) could be used to fully gauge
the effect of bFGF on breast cancer cell behaviour in the lung.
However, many other soluble factors in addition to bFGF may be contributing
to the metastatic behaviour of breast cancer within the lung. Therefore, the PuMA can
be used as a high throughput screening tool in the future for inhibiting other soluble
factors in the lung microenvironment that may have a contribution to the metastatic
progression of breast cancer. The PuMA not only represents an innovative method for
targeting specific soluble factors within the lung but also provides an avenue for
screening potential therapeutics. One disadvantage of traditional in vivo screening of
therapeutics is the sheer number of animals needed and the associated cost. With the
PuMA, many sections of lung from the same mouse/animal can be used as a much
cheaper high throughput technique for determining proper drug concentrations and
dosing regimes with many different therapeutics at once. This also has an added
advantage over traditional cell culture based screening as cells often behave
differently within a native 3D environment opposed to on 2D tissue culture plastic.
Therefore, the PuMA provides not only a unique ex vivo method for studying the
behaviour of cancer cells in a native environment but also brings the ability to screen
many different targeted and non-targeted therapeutics in a biologically relevant
setting.
Finally, another advantage of the PuMA is that it provides an appropriate
native 3D architecture onto which breast cancer cells interact. Since the PuMA is able
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to maintain lung viability throughout the duration of the assay, the architecture on
which breast cancer cells interact include both the soluble and the insoluble lung
microenvironment. Although this study focuses on specific soluble factors present
within the lung microenvironment that may be contributing to breast cancer cell
growth and behaviour, we cannot discount the importance of the insoluble
component, including the ECM. In fact, it has been shown that the ECM is a crucial
component of the metastatic niche and plays an important role in mediating the
metastatic progression of cancer [135]. A future goal of ours in collaboration with Dr.
Lauren Flynn (Western University) is the development of a decellularization protocol
to effectively eliminate the cellular presence within the lung, leaving only the
insoluble ECM scaffold. We are particularly interested in the growth patterns of both
whole population and stem-like ALDHhiCD44+ breast cancer cells in the native lung
versus a decellularized lung containing only a 3D matrix scaffold. In order to pursue
this, we are looking at assessing breast cancer behaviour in a modified version of the
PuMA. Traditionally in the PuMA, cells are seeded to the lung via the vasculature
(tail-vein injection). However, in the context of comparing between native lung and a
decellularized lung, there is no functional vasculature to utilize in seeding the lung.
Therefore, cells should instead be seeded to the lung in both the native and
decellularized lung by means of the trachea. Although this does not accurately
recapitulate what occurs physiologically, it represents a more consistent way to
compare between lung conditions. The seeding of decellularized lungs with lung
cancer cells via the trachea has been accomplished successfully by other groups and
we are confident this approach will provide an accurate avenue for comparing growth
patterns between lung conditions [89]. This work is currently underway.
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9.

FINAL CONCLUSIONS

Since the majority of deaths associated with breast cancer can be attributed to
metastasis, and more specifically to breast cancer that has spread to the lung, we
sought to determine the influence of the native lung microenvironment on the
behaviour of breast cancer cells. There are often many limitations associated with
studying the progression of metastasis in vitro. This thesis made use of an innovative
ex vivo pulmonary metastasis (PuMA) model to test the hypothesis that stem-like
ALDHhiCD44+ breast cancer cells demonstrate increased growth and progression
from a single cell stage within the native lung in relation to their non stem-like
ALDHloCD44- counterparts. Although the PuMA has been used to study the
behavioural differences between weakly and highly metastatic osteosarcoma cells
within the lung, to our knowledge, we are the first group to utilize this unique ex vivo
assay to model breast cancer metastasis within the lung, with a specific interest in the
progression differences between stem-like and non stem-like cells. This study not
only answers questions that we initially posed, but has provoked many additional
questions for the future. Therefore, this study represents a novel stepping stone for the
development of future research questions and studies.
Overall, this study supports evidence from both our lab and the literature
suggesting that small subset of tumour cells, which bear similar characteristics to
normal stem-cells, are ultimately responsible for the growth and progression of
secondary tumours after they have spread beyond the initial site of origin. We have
taken a unique approach in that we have tracked the progression of stem-like breast
cancer cell growth from the single cell stage in real time once they’ve immediately
reached the lung to study the initial steps of metastatic progression. This lung-specific
model for breast cancer metastasis has the potential to uncover key processes during
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the initial stages of lung metastasis and offers a valuable tool for future research
geared towards exploring and targeting certain aspects of the lung microenvironment,
including both the soluble and insoluble components to limit the extent of lungrelated spread in breast cancer patients.
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